EX-10.36



 EXECUTION VERSION 

Exhibit 10.36 
 ADURO
BIOTECH, INC. 
 COMMON STOCK PURCHASE AGREEMENT 

THIS COMMON STOCK PURCHASE AGREEMENT (the “Agreement”) is made as of March 12, 2015 (the “Execution
Date”) by and between Aduro Biotech, Inc., a Delaware corporation (the “Company”), and Novartis Institutes for BioMedical Research, Inc., a Delaware corporation (the “Investor”). 

RECITALS 
 WHEREAS,
pursuant to terms set forth in this Agreement the Company desires to sell to the Investor, and the Investor desires to purchase from the Company, shares of the Company’s common stock, par value $0.0001 per share (the “Common
Stock”); 
 NOW, THEREFORE, in consideration of the premises and mutual covenants herein contained, and for other good
and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows: 
 SECTION
1 
 Purchase and Sale of Shares 

1.1 Sale of Shares. Subject to the terms and conditions hereof, the Company will issue and sell to the Investor, and the
Investor will purchase from the Company, at the Closing, $25,000,000 (the “Aggregate Purchase Price”) worth of Common Stock (the “Shares”) at a price per share equal to the price per share to the
public in an underwritten initial public offering of the Common Stock (an “IPO”) pursuant to a Registration Statement under the Securities Act of 1933, as amended. 

1.2 Closing. The purchase and sale of the Shares shall take place at a closing (the “Closing”) to be
held at the offices of Cooley LLP, 3175 Hanover Street, Palo Alto, California 94304-1130, immediately following the satisfaction or waiver of each of the conditions set forth in Sections 4 and 5 hereof (other than those conditions that are to be
satisfied at the Closing, but subject to satisfaction or waiver of such conditions). At the Closing, the Company will deliver or cause to be delivered to the Investor a certificate or certificates representing the Shares that the Investor is
purchasing and, concurrently, the Investor shall pay the Aggregate Purchase Price by wire transfer in accordance with the Company’s instructions, which shall be provided in writing no later than two business days prior to the Closing Date. 








 SECTION 2 

Representations and Warranties of the Company 

Except as set forth on the Schedule of Exceptions delivered by the Company to the Investor on the date hereof, the Company hereby
represents and warrants the following as of the date hereof and as of the Closing Date (except for the representations and warranties that speak as of a specific date, which shall be made as of such date). For purposes of these representations and
warranties (other than those set forth in Sections 2.2, 2.4 and 2.6) the term “Company” includes any subsidiaries of the Company. 

2.1 Organization and Good Standing and Qualifications. The Company is a corporation duly organized, validly
existing and in good standing under the laws of the State of Delaware and has full corporate power and authority to conduct its business as presently conducted and as proposed to be conducted by it. The Company is duly qualified to do business as a
foreign corporation in California and is in good standing under the laws of such State. The Company is not required to be qualified to do business as a foreign corporation in any other jurisdiction in which the failure so to qualify would have a
material adverse effect on the business, prospects, assets or condition (financial or otherwise) of the Company (a “Company Material Adverse Effect”). The Company has furnished to the Investor complete and accurate copies of
its Certificate of Incorporation and By-laws, each as amended to date and presently in effect. The Company has at all times complied with all provisions of its Certificate of Incorporation and By-laws and is not in default under, or in violation of,
any such provision. The Company is not, and has never been, a “shell company,” as described in paragraphs (i)(1)(i) and (ii) of Rule 144 promulgated under the Securities Act of 1933, as amended (the “Securities
Act”). 
 2.2 Subsidiaries, Etc. Except as set forth in Section 2.2 of the
Schedule of Exceptions, the Company has no subsidiaries and does not own or control, directly or indirectly, any shares of capital stock of any other corporation or any interest in any partnership, limited liability company, joint venture or other
non-corporate business enterprise. 
 2.3 Authorization. The execution, delivery and performance
by the Company of this Agreement, and the consummation by the Company of the transactions contemplated hereby, have been duly authorized by all necessary corporate action. This Agreement has been duly executed and delivered by the Company and
constitutes a valid and binding obligation of the Company enforceable against the Company in accordance with its respective terms. The execution and delivery of this Agreement, the consummation of the transactions contemplated hereby and the
compliance with the provisions of this Agreement by the Company will not (a) conflict with or violate any provision of the Certificate of Incorporation or By-laws of the Company, (b) conflict with, result in a breach of, constitute (with
or without due notice or lapse of time or both) a default under, result in the acceleration of obligations under, create in any party the right to accelerate, terminate, modify or cancel, or require any notice, consent or waiver under, any contract,
lease, sublease, license, sublicense, franchise, permit, indenture, agreement or mortgage for borrowed money, instrument of indebtedness, Security Interest (as defined below) or other arrangement to which the Company is a party or by which the
Company is bound or to which its assets are subject, (c) result in the imposition of any Security Interest upon any assets of the Company or (d) violate any order, writ, injunction, decree, statute, rule or regulation applicable to the
Company or any of its  

  
 -2- 








 
properties or assets. For purposes of this Agreement, “Security Interest” means any mortgage, pledge, security interest, encumbrance, charge or other lien (whether
arising by contract or by operation of law). 
 2.4 Valid Issuance of Shares. The issuance, sale
and delivery of the Shares in accordance with this Agreement, has been, or will be on or prior to the Closing, duly authorized by all necessary corporate action on the part of the Company, and all such shares have been duly reserved for issuance.
The Shares when so issued, sold and delivered against payment therefor in accordance with the provisions of this Agreement, will be duly and validly issued, fully paid and nonassessable, and free of restrictions on transfer other than restrictions
imposed or created under this Agreement, by applicable law, or by the Investor. 
 2.5 [Intentionally omitted.] 

2.6 Capitalization. 

(a) The authorized capital stock of the Company as of the date of this Agreement consists of (i) 85,000,000 shares of Common Stock,
$0.0001 par value per share, of which 589,214 shares are issued and outstanding and none are held in the treasury of the Company, and (ii) 69,716,345 shares of Preferred Stock, $0.0001 par value per share, of which (A) 161,843 shares have
been designated as Series A Preferred, all of which are issued and outstanding, (B) 3,393,666 shares have been designated as Series A-1 Preferred, 3,369,431 of which are issued and outstanding, (C) 21,525,480 shares have been designated as
Series B Preferred, 21,441,709 of which are issued and outstanding, (D) 25,623,183 shares have been designated as Series C Preferred, all of which are issued and outstanding and (E) 19,012,173 shares have been designated as Series D
Preferred, all of which are issued and outstanding. 
 (b) Section 2.6(b) of the Schedule of Exceptions includes a complete and
accurate list, as of the date of this Agreement, of the holders of capital stock of the Company, showing the number of shares of capital stock, and the class or series of such shares, held by each stockholder and (for shares other than Common Stock)
the number of shares of Common Stock (if any) into which such shares are convertible, immediately prior to the Closing. Section 2.6(b) of the Schedule of Exceptions also indicates all outstanding shares of Common Stock that constitute
restricted stock or that are otherwise subject to a repurchase or redemption right, indicating the name of the applicable stockholder, the vesting schedule (including any acceleration provisions with respect thereto), and the repurchase price
payable by the Company. All of the issued and outstanding shares of capital stock of the Company have been duly authorized and validly issued and are fully paid and nonassessable. All of the issued and outstanding shares of capital stock of the
Company have been offered, issued and sold by the Company in compliance with all applicable federal and state securities laws. 

(c) Section 2.6(c) of the Schedule of Exceptions includes a complete and accurate list, as of the date of this Agreement
of: (i) all stock option plans and other stock or equity-related plans of the Company (the “Company Stock Plans”), indicating for each Company Stock Plan the number of shares of Common Stock issued to date under such
Plan, the number of shares subject to outstanding options under such Plan and the number of shares reserved for future issuance under such Plan; (ii) all holders of outstanding options to purchase shares of Common Stock


  
 -3- 








 
(“Company Stock Options”), indicating with respect to each Company Stock Option the Company Stock Plan under which it was granted, the number of
shares of Common Stock subject to such Company Stock Option, the exercise price, the date of grant and the vesting schedule (including any acceleration provisions with respect thereto); and (iii) all holders of warrants or other rights (other
than Company Stock Options and convertible preferred stock) to purchase or acquire shares of capital stock of the Company (collectively, the “Company Warrants”), indicating with respect to each Company Warrant the agreement
or other document under which it was granted, the number of shares of capital stock, and the class or series of such shares, subject to such Company Warrant, the exercise price, the date of issuance and the expiration date thereof. The Company has
furnished to the Investor complete and accurate copies of all Company Stock Plans, forms of all stock option agreements evidencing Company Stock Options and all Company Warrants. All of the shares of capital stock of the Company subject to Company
Stock Options and Company Warrants will be, upon issuance pursuant to the exercise of such instruments, duly authorized, validly issued, fully paid and nonassessable. 

(d) Except as set forth in Section 2.6(c) and Section 2.6(d) of the Schedule of Exceptions, (i) no subscription, warrant,
option, convertible security or other right (contingent or otherwise) to purchase or acquire any shares of capital stock of the Company is authorized or outstanding, (ii) the Company has no obligation (contingent or otherwise) to issue any
subscription, warrant, option, convertible security or other such right, or to issue or distribute to holders of any shares of its capital stock any evidences of indebtedness or assets of the Company, (iii) the Company has no obligation
(contingent or otherwise) to purchase, redeem or otherwise acquire any shares of its capital stock or any interest therein or to pay any dividend or to make any other distribution in respect thereof, and (iv) there are no outstanding or
authorized stock appreciation, phantom stock or similar rights with respect to the Company. 
 (e) Except as set forth in
Section 2.6(e) of the Schedule of Exceptions, there is no agreement, written or oral, between the Company and any holders of its securities, or, to the best of the Company’s knowledge, among any holder of its securities, relating to the
sale or transfer (including without limitation agreements relating to rights of first refusal, co sale rights or “drag along” rights), registration under the Securities Act, or voting, of the capital stock of the Company. 

2.7 Financial Statements. The Company has furnished to the Investor a complete and accurate copy of (a) the
audited balance sheet of the Company at December 31, 2014 (the “Balance Sheet Date”) and the related audited statement of operations for the fiscal year then ended (collectively, the “Financial
Statements”). The Financial Statements are in accordance with the books and records of the Company and present fairly the financial condition and results of operations of the Company, at the dates and for the periods indicated.

 2.8 Material Adverse Change. Except as set forth in Section 2.8 of the Schedule of Exceptions,
since the Balance Sheet Date, there has not been: 
 (a) any change in the assets, liabilities, financial condition or
operating results of the Company from that reflected in the Financial Statements, except changes in the ordinary course of business that have not caused, in the aggregate, a Company Material Adverse Effect; 

  
 -4- 








 (b) any damage, destruction or loss, whether or not covered by insurance, that would have a
Company Material Adverse Effect; 
 (c) any waiver or compromise by the Company of a valuable right or of a material debt owed to it; 

(d) any satisfaction or discharge of any lien, claim, or encumbrance or payment of any obligation by the Company, except in the ordinary
course of business and the satisfaction or discharge of which would not have a Company Material Adverse Effect; 
 (e) any material change
to a material contract or agreement by which the Company or any of its assets is bound or subject; 
 (f) any material change in any
compensation arrangement or agreement with any employee, officer, director or stockholder; 
 (g) any resignation or termination of
employment of any officer or Key Employee of the Company; 
 (h) any mortgage, pledge, transfer of a security interest in, or lien, created
by the Company, with respect to any of its material properties or assets, except liens for taxes not yet due or payable and liens that arise in the ordinary course of business and do not materially impair the Company’s ownership or use of such
property or assets; 
 (i) any loans or guarantees made by the Company to or for the benefit of its employees, officers or directors, or any
members of their immediate families, other than travel advances and other advances made in the ordinary course of its business; 
 (j) any
declaration, setting aside or payment or other distribution in respect of any of the Company’s capital stock, or any direct or indirect redemption, purchase, or other acquisition of any of such stock by the Company; 

(k) any sale, assignment or transfer of any Company Intellectual Property that could reasonably be expected to result in a Company Material
Adverse Effect; 
 (l) receipt of notice that there has been a loss of, or material order cancellation by, any major customer of the
Company; 
 (m) to the Company’s knowledge, any other event or condition of any character, other than events affecting the economy or
the Company’s industry generally, that could reasonably be expected to result in a Company Material Adverse Effect; or 
 (n) any
arrangement or commitment by the Company to do any of the things described in this Section 2.8. 
 2.9 No Undisclosed
Liabilities. Except as set forth in Section 2.9 of the Schedule of Exceptions, the Company does not have any liability (whether known or unknown and whether absolute or contingent), except for (a) liabilities shown expressly, or
included in amounts shown, on 

  
 -5- 








 
the Balance Sheet, (b) liabilities less than $250,000 on an individual basis, which have arisen since the Balance Sheet Date in the ordinary course of business and which are similar in
nature and amount to the liabilities which arose during the comparable period of time in the immediately preceding fiscal period and (c) contractual liabilities incurred in the ordinary course of business which are not required by GAAP to be
reflected on a balance sheet and which would not, either individually or in the aggregate, have or result in a Company Material Adverse Effect. 

2.10 Governmental Consents. No consent, approval, order or authorization of, or registration, qualification,
designation, declaration or filing with, any court, arbitrational tribunal, administrative agency or commission or other governmental or regulatory authority or agency (each of the foregoing is hereafter referred to as a “Governmental
Entity”) is required on the part of the Company in connection with the offer, issuance, sale and delivery of the Shares, as contemplated by this Agreement, except such filings as shall have been made prior to and shall be effective on
and as of the Closing and such filings required to be made after the Closing under applicable federal and state securities laws, all of which filings are specified in the Schedule of Exceptions. Based on the representations made by the Investor in
Section 3 of this Agreement, the offer and sale of the Shares to the Investor will be in compliance with applicable federal and state securities laws. 

2.11 Actions Pending. There is no action, suit or proceeding, or governmental inquiry or investigation, pending,
or, to the best of the Company’s knowledge, any basis therefor or threat thereof, against the Company or any officer, director or Key Employee of the Company, which questions the validity of this Agreement or the right of the Company to enter
into such agreement or to consummate the transactions contemplated hereby. There is no litigation pending, or, to the best of the Company’s knowledge, any basis therefor or threat thereof, against the Company or any of its employees by reason
of the past employment relationships of any of the employees, the proposed activities of the Company, or negotiations by the Company with possible investors in the Company. The Company is not subject to any outstanding judgment, order or
decree. 
 2.12 Foreign Corrupt Practices Act, OFAC and Anti-Money Laundering. 

(a) None of the Company, its subsidiaries or, to the knowledge of the Company, any of the Company’s directors, officers,
employees or agents has taken any action, directly or indirectly, that would result in a violation by such persons of the Foreign Corrupt Practices Act of 1977, as amended, and the rules and regulations thereunder (the
“FCPA”), including, without limitation, making use of the mails or any means or instrumentality of interstate commerce corruptly in furtherance of an offer, payment, promise to pay or authorization of the payment of any
money, or other property, gift, promise to give, or authorization of the giving of anything of value to any “foreign official” (as such term is defined in the FCPA) or any foreign political party or official thereof or any candidate for
foreign political office, in contravention of the FCPA and the Company and its subsidiary have conducted their businesses in compliance with the FCPA and have instituted and maintain policies and procedures designed to ensure, and which are
reasonably expected to continue to ensure, continued compliance therewith. 
 (b) Neither the Company nor any of
its subsidiaries nor, to the knowledge of the Company, any director, officer, agent, employee, or person acting on behalf of the Company or any subsidiary is currently subject to any U.S. sanctions administered by the Office of Foreign Assets
Control of the U.S. Treasury Department (“OFAC”), and the Company will not directly or  

  
 -6- 








 
indirectly use the proceeds of the sale of the Shares, or lend, contribute or otherwise make available such proceeds to any subsidiary, joint venture partner or other person or entity, towards
any sales or operations in Cuba, Iran, Syria, Sudan, Myanmar or any other country sanctioned by OFAC or for the purpose of financing the activities of any person currently subject to any U.S. sanctions administered by OFAC. 

(c) The operation of each of the Company and its subsidiaries are and have been conducted at all times in compliance with the money laundering
statues of applicable jurisdictions, the rules and regulations thereunder and any related or similar rules, regulations or guidelines, issued, administered or enforced by any applicable governmental agency (collectively, the “Money
Laundering Laws”), and no action suit or proceeding by or before any court of governmental agency, authority or body or any arbitrator involving the Company and/or any subsidiary with respect to the Money Laundering Laws is pending, or
to the Company’s knowledge, threatened. 
 2.13 Data Privacy. In connection with its collection, storage,
transfer (including, without limitation, any transfer across national borders) and/or use of any personally identifiable information from any individuals, including, without limitation, any customers, prospective customers, employees and/or other
third parties (collectively “Personal Information”), the Company is and has been in compliance with all applicable laws in all relevant jurisdictions, the Company’s privacy policies and the requirements of any contract
or codes of conduct to which the Company is a party. The Company has commercially reasonable physical, technical, organizational and administrative security measures and policies in place to protect all Personal Information collected by it or on its
behalf from and against unauthorized access, use and/or disclosure. The Company is and has been in compliance in all material respects with all laws relating to data loss, theft and breach of security notification obligations 

2.14 Compliance with Law. The Company has, in all material respects, complied with all laws, regulations and
orders applicable to its present and proposed business and has all material permits and licenses required thereby. There is no term or provision of any mortgage, indenture, contract, agreement or instrument to which the Company is a party or by
which it is bound, or, to the best of the Company’s knowledge, of any provision of any state or federal judgment, decree, order, statute, rule or regulation applicable to or binding upon the Company, which materially adversely affects or, so
far as the Company may now foresee, in the future is reasonably likely to materially adversely affect the Company. To the best of the Company’s knowledge, no employee of the Company is in violation of any term of any contract or covenant
(either with the Company or with another entity) relating to employment, patents, assignment of inventions, proprietary information disclosure, non-competition or non-solicitation. 

2.15 Exemption from Registration, Valid Issuance. Subject to, and in reliance on, the representations, warranties
and covenants made herein by the Investor, the issuance and sale of the Shares in accordance with the terms and on the bases of the representations and warranties set forth in this Agreement, may and shall be properly issued pursuant to
Section 4(a)(2) of the Securities Act, Regulation D promulgated pursuant to the Act (“Regulation D”) and/or any other applicable federal and state securities laws. The sale and issuance of the Shares pursuant to,
and the Company’s performance of its obligations under, this Agreement will not (i) result in the creation or imposition of any liens, charges, claims or other encumbrances upon the Shares or any of the assets of the 


  
 -7- 








 
Company, or (ii) except as set forth in Section 2.15 of the Schedule of Exceptions, entitle the holders of any outstanding shares of capital stock of the Company to preemptive or other
rights to subscribe to or acquire the Shares or other securities of the Company. 
 2.16 Taxes.  

(a) For purposes of this Agreement: (i) “Tax” or “Taxes” means all taxes, charges, fees, levies
or other similar assessments or liabilities, including without limitation income, gross receipts, ad valorem, premium, value-added, excise, real property, personal property, sales, use, transfer, withholding, employment, unemployment insurance,
social security, business license, business organization, environmental, workers compensation, payroll, profits, license, lease, service, service use, severance, stamp, occupation, windfall profits, customs, duties, franchise and other taxes imposed
by the United States of America or any state, local or foreign government, or any other Governmental Entity, and any interest, fines, penalties, assessments or additions to tax resulting from, attributable to or incurred in connection with any tax
or any contest or dispute thereof, and any liability for the payment of the foregoing as a result of being a member of an affiliated, combined, consolidated or unitary group for any period, as a result of any tax sharing or tax allocation agreement,
arrangement or understanding, or as a result of being liable for another person’s taxes as a transferee or successor, by contractual obligation or otherwise; and (ii) “Tax Returns” means all reports, returns, declarations,
statements or other information, including any schedule or attachment thereto, required to be supplied to a taxing authority in connection with Taxes and any amendment thereof. 

(b) The amount shown on the Balance Sheet as provision for Taxes is sufficient in all material respects for the payment of all
unpaid Taxes, whether or not disputed, for all periods ending on or before the date thereof. The Company has timely filed or obtained presently effective extensions with respect to all Tax Returns that are or were required to be filed by it, and
such Tax Returns are complete and accurate in all material respects. All Taxes have been timely paid, whether or not shown on such Tax Returns. All Taxes that the Company is or was required by law to have withheld or collected have been duly
withheld or collected and, to the extent required, have been timely paid to the proper Governmental Entity, and the Company has complied with all related recordkeeping requirements. The Tax Returns of the Company have not been audited by any
Governmental Entity, the Company has not agreed to any waivers of statutes of limitations with respect to Taxes, and no controversy with respect to Taxes is pending or, to the best of the Company’s knowledge, threatened. No claim has ever been
made by any Governmental Entity in a jurisdiction where the Company does not file Tax Returns that the Company is or may be subject to taxation by that jurisdiction, and, to the Company’s knowledge, there is no basis for any such claim to be
made. Neither the Company nor any of its stockholders has ever filed an election pursuant to Section 1362 of the Internal Revenue Code of 1986, as amended (the “Code”), that the Company be taxed as an S corporation. The
Company’s net operating losses, as set forth in the Financial Statements, are not subject to any limitations imposed by Section 382 of the Code or comparable provisions of state, local, or foreign law, and consummation of the transactions
contemplated by this Agreement or by any other agreement, understanding or commitment, contingent or otherwise, to which the Company is a party or by which it is otherwise bound will not have the effect of limiting the Company’s ability to use
such net operating losses in full to offset taxable income. The Company does not have any liabilities for Taxes of any other person or entity by contract, as a transferee or successor, under U.S. Treasury Regulation section 1.1502-6 or analogous
state, county, local or foreign provision or otherwise. 

  
 -8- 








 (c) The Company is not now and has never been a “United States real property holding
corporation” as defined in Section 897(c)(2) of the Code and the Treasury Regulations thereunder. 
 2.17
Investment Company. The Company is not an investment company within the meaning of the Investment Company Act of 1940, as amended. 

2.18 Shell Company. The Company is not, and has never been, an issuer identified in Rule 144(i)(1) promulgated
under the Securities Act 
 2.19 Brokers. Except as set forth in Section 2.19 of the Schedule
of Exceptions, no brokers, finders or financial advisory fees or commissions will be payable by the Company or any of its subsidiaries in respect of the transactions contemplated by this Agreement. 

2.20 Property and Assets. The Company has good title to, or a valid leasehold interest in, all of its material
properties and assets, including all properties and assets reflected in the Balance Sheet, except those disposed of since the date thereof in the ordinary course of business, and none of such properties or assets is subject to any Security Interest
other than those the material terms of which are described in the Balance Sheet or in the Schedule of Exceptions. 
 2.21
Intellectual Property. 
 (a) The Schedule of Exceptions includes a complete and accurate list of (i) each
patent, patent application, copyright registration or application therefor, and trademark, service mark and domain name registration or application therefor of the Company and (ii) each Product Candidate (as defined below) owned or in-licensed
by the Company. 
 (b) To the best of the Company’s Knowledge, the Company is the owner, licensee or has the right to use all Company
Intellectual Property (as defined below) necessary (i) to research, develop, use, manufacture, market and sell the Product Candidates and (ii) to operate the Internal Systems (as defined below). The Company has taken all reasonable
measures to protect the proprietary nature of each item of Company Intellectual Property (as defined below), and to maintain in confidence all trade secrets and confidential information, that it owns or uses. To the best of the Company’s
Knowledge, (i) the patents and patent applications that constitute Company Intellectual Property have been prepared, filed and prosecuted in accordance with all applicable laws and regulations and (ii) any issued patents that constitute
Company Intellectual Property are valid or enforceable. To the best of the Company’s Knowledge, no other person or entity has any rights to any of the Company Intellectual Property owned by the Company (except pursuant to agreements or licenses
specified in the Schedule of Exceptions), and no other person or entity is infringing, violating or misappropriating any of the Company Intellectual Property. To the best of the Company’s Knowledge, there are no pending or threatened legal or
governmental proceedings relating to any Company Intellectual Property, other than ex parte examination proceedings before the US Patent and Trademark Office or ex parte examination proceedings or oppositions before corresponding foreign patent
offices. 

  
 -9- 








 (c) To the best of the Company’s Knowledge, as of the date of this Agreement, none of the
Product Candidates, or the research, development, manufacture, marketing, sale, offer to sell, importation, provision or use thereof, infringes or would infringe, or violates or would violate, or constitutes or would constitute a misappropriation
of, any Intellectual Property rights of any person or entity. To the best of the Company’s Knowledge, none of the Internal Systems, or the use thereof, infringes or violates, or constitutes a misappropriation of, any Intellectual Property
rights of any person or entity. The Schedule of Exceptions lists any complaint, claim or notice, or written threat thereof, received by the Company alleging any such infringement, violation or misappropriation; and the Company has provided to the
Investor complete and accurate copies of all written documentation in the possession of the Company relating to any such complaint, claim, notice or threat. The Company has furnished to the Investor complete and accurate copies of all written
documentation in the Company’s possession relating to claims or disputes (including without limitation as to validity, inventorship, ownership or enforceability) known to the Company concerning any Company Intellectual Property. 

(d) The Schedule of Exceptions identifies each license or other agreement, including material transfer agreements, pursuant to which the
Company has licensed, distributed or otherwise granted any rights to any third party or which the licensor or inventor has granted any rights with respect to, any Company Intellectual Property. Except as described in the Schedule of Exceptions, the
Company has not agreed to indemnify any person or entity against any infringement, violation or misappropriation of any Intellectual Property rights with respect to any Company Intellectual Property. 

(e) The Schedule of Exceptions identifies each item of Company Intellectual Property that is owned by a party other than the Company, and the
license or agreement pursuant to which the Company uses it (excluding off-the-shelf software programs licensed by the Company pursuant to “shrink wrap” or “click through” licenses). 

(f) All of the copyrightable materials incorporated in, underlying or used with the Company Intellectual Property have been created by
employees of the Company within the scope of their employment by the Company or by independent contractors of the Company who have executed agreements expressly assigning all right, title and interest in such copyrightable materials to the Company.
No portion of such copyrightable materials was jointly developed with any third party. 
 (g) For purposes of this Agreement (except for the
knowledge definition below, which shall be applicable solely to this Section 2.21), the following terms shall have the following meanings: 

(i) “Company Intellectual Property” shall mean the Intellectual Property owned by or licensed to the
Company and incorporated in, underlying or used in connection with the Product Candidates or the Internal Systems, including, without limitation, the patent and trademark rights identified in the Schedule of Exceptions. 

(ii) “Intellectual Property” shall mean all: (A) patents, patent applications, patent disclosures
and all related continuation, continuation-in-part, divisional, reissue, reexamination, utility model, certificate of invention and design patents, patent applications,  

  
 -10- 








 
registrations and applications for registrations; (B) trademarks, service marks, trade dress, Internet domain names, logos, trade names and corporate names and registrations and applications
for registration thereof; (C) copyrights and registrations and applications for registration thereof; (D) computer software, data and documentation; (E) inventions, trade secrets and confidential business information, whether
patentable or nonpatentable and whether or not reduced to practice, know-how, manufacturing and product processes and techniques, formulae, research and development information, copyrightable works, financial, marketing and business data, pricing
and cost information, business and marketing plans and customer and supplier lists and information; (F) other proprietary rights relating to any of the foregoing (including remedies against infringements thereof and rights of protection of
interest therein under the laws of all jurisdictions); and (G) copies and tangible embodiments thereof. 
 (iii)
“Internal Systems” shall mean the internal systems of the Company that are used in its business or operations, including, computer hardware systems, software applications and embedded systems.  

(iv) “Key Employees” shall mean the following officers: Dirk G. Brockstedt, Thomas Dubensky, Jr.,
Stephen T. Isaacs, Jennifer Lew and Gregory Schafer.  
 (v) “Knowledge,” including the
phrase “to the Company’s Knowledge,” shall mean the actual knowledge after reasonable investigation of the Key Employees. 

(vi) “Product Candidates” shall mean (A) the therapeutic vaccines and other products that the
Company (1) currently develops, manufactures, markets, sells or licenses or (2) currently plans to develop, manufacture, market, sell or license in the future and (B) the services that the Company (1) currently provides or
(2) currently plans to provide in the future. 
 2.22 Insurance. The Company maintains valid
policies of workers’ compensation insurance and of insurance with respect to its properties and business of the kinds and in the amounts not less than is customarily obtained by corporations of established reputation engaged in the same or
similar business and similarly situated, including, without limitation, insurance against loss, damage, fire, theft, public liability and other risks. 

2.23 Material Contracts and Obligations. The Schedule of Exceptions sets forth a list of all material agreements
or commitments of any nature (whether written or oral) to which the Company is a party or by which it is bound, including without limitation (a) any agreement which requires future expenditures by the Company in excess of $500,000 or which
might result in payments to the Company in excess of $500,000, (b) any employment agreement, employee benefit, bonus, pension, profit-sharing, stock option, stock purchase or similar plan or arrangement, (c) any distributor, sales
representative or similar agreement, (d) any agreement with any current or former stockholder, officer or director of the Company, or any “affiliate” or “associate” of such persons (as such terms are defined in the rules and
regulations promulgated under the Securities Act), including without limitation any agreement or other arrangement providing for the furnishing of services by, rental of real or personal property from, or otherwise requiring payments to, any such
person or entity, (e) any agreement under which the Company is restricted from carrying on any business anywhere in the world, (f) any agreement relating to indebtedness for borrowed money, (g) any agreement for the disposition of a
material portion of the Company’s assets (other than for the sale  

  
 -11- 








 
of inventory in the ordinary course of business), (h) any agreement for the acquisition of the business or securities or other ownership interests of another party, (i) any agreement
for the license of any patent, copyright, trademark, trade secret or other proprietary right to or from the Company (other than licenses by the Company of “off the shelf” or other commercially available standard products) or (j) any
other agreement that is material to the operations, business or finances of the Company. The Company has furnished to the Investor copies of the foregoing agreements (or an accurate summary of any oral agreement). All of such agreements and
contracts are valid, binding against the Company and in full force and effect. Neither the Company, nor, to the best of the Company’s knowledge, any other party thereto, is in default of any of its obligations under any of the agreements or
contracts listed in the Schedule of Exceptions. 
 2.24 Employees. 

(a) All current and former employees of the Company have executed and delivered Confidential Information and Inventions Assignments and
Non-Solicitation Agreements in the form of Exhibit A and all of such agreements are in full force and effect. All current and former consultants of the Company that have performed development work or provided technical services to the Company
or have otherwise had access to confidential or proprietary information of the Company have executed and delivered non-disclosure and assignment of inventions agreements copies of which have been made available to the Investor, and all of such
agreements are in full force and effect. 
 (b) The Company is not aware that any employee of the Company has plans to terminate his or her
employment relationship with the Company. Except as set forth in Section 2.24(b) of the Schedule of Exceptions, all employees of the Company are engaged by the Company on a full time basis. The Company has complied in all material respects with
all applicable laws relating to wages, hours, equal opportunity, collective bargaining, workers’ compensation insurance and the payment of social security and other Taxes. None of the employees of the Company is represented by any labor union,
and there is no labor strike or other labor trouble pending with respect to the Company (including, without limitation, any organizational drive) or, to the best of the Company’s knowledge, threatened. The Schedule of Exceptions sets forth a
list of all agreements between any officer of the Company and a previous employer of such person that contains non-competition or non-solicitation covenants. The Company has furnished to the Investor copies of such agreements. To the Company’s
knowledge, no employee of the Company is obligated under any contract or subject to any judgment, decree or administrative order that would conflict or interfere with (i) the performance of the employee’s duties as an employee, director or
officer of the Company, or (ii) the Company’s business as conducted or proposed to be conducted. 
 (c) The Schedule of Exceptions
sets forth (i) the annual salary, (ii) any bonus arrangements and (iii) rights, options or warrants to subscribe for, purchase or otherwise acquire Common Stock of each of the Key Employees. 

2.25 ERISA. Except as set forth in Section 2.25 of the Schedule of Exceptions, the Company does not have or
otherwise contribute to or participate in any employee benefit plan subject to the Employee Retirement Income Security Act of 1974, as amended, other than a medical benefit plan with respect to which the Company has made all required
contributions and has complied with all applicable laws. 

  
 -12- 








 2.26 Books and Records. The minute books of the Company contain
complete and accurate records of all meetings and other corporate actions of its stockholders and its Board of Directors and committees thereof. The stock ledger of the Company is complete and accurate and reflects all issuances, transfers,
repurchases and cancellations of shares of capital stock of the Company. 
 2.27 Permits. The
Schedule of Exceptions sets forth a list of all material permits, licenses, registrations, certificates, orders or approvals from any Governmental Entity (“Permits”) issued to or held by the Company. Such listed Permits are
the only Permits that are required for the Company to conduct its business as presently or proposed to be conducted, except for those the absence of which would not have a Company Material Adverse Effect. Each such Permit is in full force and effect
and, to the best of the Company’s Knowledge, no suspension or cancellation of such Permit is threatened and there is no basis for believing that such Permit will not be renewable upon expiration 

2.28 Environmental Matters. 

(a) The Company has complied with all applicable Environmental Laws (as defined below). There is no pending or, to the best of
the Company’s knowledge, threatened civil or criminal litigation, written notice of violation, formal administrative proceeding, or investigation, inquiry or information request by any Governmental Entity, relating to any Environmental Law
involving the Company. For purposes of this Agreement, “Environmental Law” shall mean any federal, state or local law, statute, rule or regulation or the common law relating to the environment or occupational health and
safety, including any statute, regulation, administrative decision or order pertaining to (i) treatment, storage, disposal, generation and transportation of industrial, toxic or hazardous materials or substances or solid or hazardous waste;
(ii) air, water and noise pollution; (iii) groundwater and soil contamination; (iv) the release or threatened release into the environment of industrial, toxic or hazardous materials or substances, or solid or hazardous waste,
including emissions, discharges, injections, spills, escapes or dumping of pollutants, contaminants or chemicals; (v) the protection of wildlife, marine life and wetlands, including all endangered and threatened species; (vi) storage
tanks, vessels, containers, abandoned or discarded barrels and other closed receptacles; (vii) health and safety of employees and other persons; and (viii) manufacturing, processing, using, distributing, treating, storing, disposing,
transporting or handling of materials regulated under any law as pollutants, contaminants, toxic or hazardous materials or substances or oil or petroleum products or solid or hazardous waste. As used above, the terms
“release” and “environment” shall have the meaning set forth in the federal Comprehensive Environmental Response, Compensation and Liability Act of 1980, as
amended (“CERCLA”), provided that the term “release” shall not include the definitional exclusions of CERCLA and the term “environment” shall not include the United States
jurisdictional limitations of CERCLA and shall include the indoor environment. 
 (b) The Company has no
liabilities or obligations arising from the release of any Materials of Environmental Concern (as defined below) into the environment. For purposes of this Agreement, “Materials of Environmental Concern” shall mean any
chemicals, pollutants or 

  
 -13- 








 
contaminants, hazardous substances (as such term is defined under CERCLA), solid wastes and hazardous wastes (as such terms are defined under the Resource Conservation and
Recovery Act), toxic materials, oil or petroleum and petroleum products or any other material subject to regulation under any Environmental Law. 

(c) The Company is not a party to or bound by any court order, administrative order, consent order or other agreement between the Company and
any Governmental Entity entered into in connection with any legal obligation or liability arising under any Environmental Law. 
 (d) The
Company is not aware of any material environmental liability of any solid or hazardous waste transporter or treatment, storage or disposal facility that has been used by the Company. 

(e) Set forth in the Schedule of Exceptions is a list of all documents (whether in hard copy or electronic form) that contain any
environmental reports, investigations and audits relating to premises currently or previously owned or operated by the Company (whether conducted by or on behalf of the Company or a third party, and whether done at the initiative of the Company or
directed by a Governmental Entity or other third party) which the Company has possession of or access to. A complete and accurate copy of each such document has been provided to the Investor. 

2.29 Disclosure. Neither this Agreement nor any Exhibit hereto, nor any report, certificate
or instrument furnished by the Company to any of the Investor or its counsel in connection with the transactions contemplated by this Agreement, when read together, contains or will contain any untrue statement of a material fact or omits or will
omit to state a material fact necessary in order to make the statements contained herein or therein, in light of the circumstances under which they were made, not misleading. 

2.30 Bad Actors Matters. Neither the Company nor, to the Company’s knowledge, any of its officers, directors
or other affiliates covered under Rule 506(d)(1) promulgated under the Securities Act (excluding for such purposes the Investor) meet any of the disqualifying criteria described in Rule 506(d)(1)(i) through (viii) promulgated under the
Securities Act. 
 SECTION 3 

Representations and Warranties of the Investor 

The Investor hereby represents and warrants the following as of the date hereof and as of the Closing Date: 

3.1 Experience. The Investor has carefully reviewed the representations concerning the Company contained in this
Agreement and has sufficient knowledge and experience in finance and business that it is capable of evaluating the risks and merits of its investment in the Company and the Investor is able financially to bear the risks thereof. 

  
 -14- 








 3.2 Investment. The Investor is acquiring the Shares for investment
for the Investor’s own account and not with the view to, or for resale in connection with, any distribution thereof. The Investor understands that the Shares are being issued in a transaction that has not been and will not be registered under
the Securities Act by reason of a specific exemption from the registration provisions of the Securities Act which depends upon, among other things, the bona fide nature of the investment intent as expressed herein. The Investor further represents
that it does not have any contract, undertaking, agreement or arrangement with any person to sell, transfer or grant participation to any third person with respect to any of the Shares.  

3.3 Rule 144. The Investor acknowledges that the Shares must be held indefinitely unless subsequently
registered under the Securities Act or an exemption from such registration is available. The Investor is aware of the provisions of Rule 144 promulgated under the Securities Act which permit limited resale of shares purchased in a private
placement subject to the satisfaction of certain conditions. In connection therewith, the Investor acknowledges that the Company will make a notation on its stock books regarding the restrictions on transfers set forth in this Section 3 and
will transfer the Shares on the books of the Company only to the extent not inconsistent therewith. 
 3.4
Access to Information. The Investor has received and reviewed information about the Company and has had an opportunity to discuss the Company’s business, management and financial affairs with its management and to review the
Company’s facilities. The Investor has had a full opportunity to ask questions of and receive answers from the Company, or any person or persons acting on behalf of the Company, concerning the terms and conditions of an investment in the
Shares. In connection with the purchase of the Shares hereunder, the Investor is not relying upon, and has not relied upon, any statement, representation or warranty made by any person, except for the statements, representations and warranties
contained in this Agreement. 
 3.5 Authorization. The Investor has full power and authority to
enter into and to perform this Agreement in accordance with its terms. The Investor represents that it has not been organized, reorganized or recapitalized specifically for the purpose of investing in the Company. This Agreement has been duly
executed and delivered by the Investor and constitutes a valid and binding obligation of the Investor enforceable against the Investor in accordance with their respective terms. 

3.6 Investor Status. The Investor acknowledges that it is either (i) an institutional “accredited
investor” as defined in Rule 501(a) of Regulation D of the Securities Act (an “Institutional Accredited Investor”) or (ii) a “qualified institutional buyer” as defined in Rule 144A of the
Securities Act, as indicated on Schedule A hereto, and the Investor shall submit to the Company such further assurances of such status as may be reasonably requested by the Company. 

3.7 No Inducement. The Investor was not induced to participate in the offer and sale of the Shares by the filing
of any registration statement in connection with any public offering of the Company’s securities, and the Investor’s decision to purchase the Shares hereunder was not influenced by the information contained in any such registration
statement. 

  
 -15- 








 SECTION 4 

Conditions to Investor’s Obligations at Closing 

The obligations of the Investor under this Agreement are subject to the fulfillment on or before the Closing of each of the following
conditions, any of which may be waived in writing by the Investor (except to the extent not permitted by law): 
 4.1 No
Injunction, etc. No preliminary or permanent injunction or other binding order, decree or ruling issued by a court or governmental agency shall be in effect which shall have the effect of preventing the consummation of the transactions
contemplated by this Agreement. No action or claim shall be pending before any court or quasi-judicial or administrative agency of any federal, state, local or foreign jurisdiction or before any arbitrator wherein an unfavorable injunction,
judgment, order, decree, ruling or charge would be reasonably likely to (i) prevent consummation of any of the transactions contemplated by this Agreement, (ii) cause any of the transactions contemplated by this Agreement to be rescinded
following consummation or (iii) have the effect of making illegal the purchase of, or payment for, any of the Shares by the Investor. 

4.2 Representations and Warranties. The representations and warranties of the Company contained in Section 2
shall have been true and correct in all material respects (except for such representations and warranties that are qualified by materiality, which shall be true and correct in all respects) on and as of the Closing Date with the same effect as
though such representations and warranties had been made on and as of such date, except to the extent expressly made as of a specified date, which shall be true and correct as of such date. 

4.3 Performance. The Company shall have performed and complied with all covenants, agreements, obligations and
conditions contained in this Agreement that are required to be performed or complied with by it on or before the Closing Date. 

4.4 Compliance Certificate. A duly authorized officer of the Company shall deliver to the Investor at the Closing
a certificate stating that the conditions specified in Sections 4.2 and 4.3 have been fulfilled and certifying and attaching the Company’s Certificate of Incorporation, Bylaws and authorizing Board of Directors resolutions with respect to
this Agreement and the transactions contemplated hereby. 
 4.5 Securities Laws. The offer and
sale of the Shares to the Investor pursuant to this Agreement shall be exempt from the registration requirements of the Securities Act and the registration and/or qualification requirements of all applicable state securities laws. 

4.6 Authorizations. All authorizations, approvals or permits, if any, of any governmental authority or regulatory
body that are required in connection with the lawful issuance and sale of the Shares pursuant to this Agreement shall have been duly obtained and shall be effective on and as of the Closing. 

4.7 Legal Opinion. The Investor shall have received a legal opinion from Cooley LLP substantially in form and substance
reasonably acceptable to the Investor. 
 4.8 Effective Date. The Effective Date (as such
term is described in the that certain Collaboration and License Agreement (the “Collaboration Agreement”), entered into as of March 12, 2015, between the Company and Novartis Pharmaceuticals Corporation) shall have
occurred. 

  
 -16- 








 4.9 IPO. The Company shall have consummated an IPO. 

SECTION 5 
 Conditions
to the Company’s Obligations at Closing 
 The obligations of the Company to the Investor under this Agreement are subject to the
fulfillment on or before the Closing of each of the following conditions by the Investor: 
 5.1 Representations and
Warranties. The representations and warranties of the Investor contained in Section 3 shall be true and correct in all material respects (except for such representations and warranties that are qualified by materiality which shall be
true and correct in all respects) on and as of the Closing with the same effect as though such representations and warranties had been made on and as of the Closing. 

5.2 Securities Law Compliance. The offer and sale of the Shares to the Investor pursuant to this Agreement shall
be exempt from the registration requirements of the Securities Act and the registration and/or qualification requirements of all applicable state securities laws. 

5.3 Authorization. All authorizations, approvals or permits, if any, of any governmental authority or regulatory body
that are required in connection with the lawful issuance and sale of the Shares pursuant to this Agreement shall have been duly obtained and shall be effective on and as of the Closing. 

SECTION 6 
 Investor
Covenants 
 6.1 Trading Restrictions. 

(a) Definitions. 

(i) “Affiliate” shall have the meaning set forth in Rule 12b-2 of the regulations promulgated under the Securities
Exchange Act of 1934, as amended (the “Exchange Act”).  
 (ii) “Restriction Period” shall mean
the period commencing on the Closing Date and continuing until the earlier of (A) the two year anniversary of the Closing Date and (B) the date upon which the Collaboration Agreement expires or is terminated in accordance with its
terms. 
 (iii) “Significant Event” shall mean any of the following not involving a violation of this
Section 6: (A) the public announcement of a proposal or intention to acquire, or the acquisition, by any person or 13D Group of beneficial ownership of Voting Securities representing 15% or more of the then outstanding Voting Securities,
or all or substantially all of the assets of the Company; (B) the public announcement of a proposal or intention to commence, or the commencement, by any person or 13D Group of a tender or exchange offer to acquire Voting


  
 -17- 








 
Securities which, if successful, would result in such person or 13D Group owning, when combined with any other Voting Securities owned by such person or 13D Group, 15% or more of the then
outstanding Voting Securities; (C) the entry into by the Company, or the public announcement by the Company of an intention or determination to enter into or commence or continue any discussions relating to, any merger, sale or other business
combination transaction, or an agreement therefor, pursuant to which the outstanding shares of capital stock of the Company would be converted into cash, other consideration or securities of another person or 13D Group or 50% or more of the then
outstanding shares of capital stock of the Company would be owned by persons other than the then current holders of shares of capital stock of the Company, or which would result in all or a substantial portion of the Company’s assets being sold
to any person or 13D Group, or (D) entering into an agreement or commencing a proxy solicitation in which a person or 13D Group would, if successful, elect, or acquire the ability to elect, a majority of the Board of Directors of the Company.

 (iv) “Voting Securities” shall mean at any time shares of any class of capital stock of the Company which are
then entitled to vote generally in the election of directors. 
 (v) “13D Group” shall mean, with respect to
the Voting Securities of the Company, any group of persons formed for the purpose of acquiring, holding, voting or disposing of such Voting Securities which would be required under Section 13(d) of the Exchange Act and the rules and regulations
thereunder to file a statement on Schedule 13D with the Commission as a “person” within the meaning of Section 13(d)(3) of the Exchange Act if such group beneficially owned Voting Securities representing more than 5% of the total
combined voting power of all such Voting Securities then outstanding. 
 (b) Restriction Period No Sell. The Investor agrees
that during the Restriction Period, neither the Investor nor any of its Affiliates shall offer, sell, contract to sell, pledge, grant any option to purchase, make any short sale or otherwise dispose of in any manner, either directly or indirectly
(“Sale” or “Sell”), any Shares or any securities of the Company issued as a dividend or distribution on, or involving a recapitalization or reorganization with respect to, any of the Shares
(“Covenant Shares”), other than transfers of securities between and among the Investor and any one or more of its Affiliates. The Company shall use commercially reasonable efforts to permit the Shares to be eligible for
clearance and settlement through the facilities of The Depository Trust Company immediately following the termination of the Restriction Period. 

(c) Post-Restriction Period Selling Restrictions. During the two years following the expiration of the Restriction Period: 

(i) Neither the Investor nor its Affiliates shall Sell a number of Covenant Shares in any three-month period that collectively exceeds 25% of
the aggregate Covenant Shares held by the Investor and its Affiliates as of the end of the Restriction Period; and 
 (ii) For any proposed
Sale of 100,000 or more shares of Common Stock of the Company by the Investor or any of its Affiliates in any single transaction or series of related transactions (“Proposed Sale Shares”), the Investor shall
give the Company at least 10 days prior written notice of such sale. If the Investor provides a notice as provided in the preceding sentence, during such 10-day period, the Company may seek to find a buyer for the Proposed Sale Shares. The
limitations and obligations set forth in this Section 6.1(c) shall not apply to any Sale of Covenant Shares taking place between the Investor (and/or any of its Affiliates) and a single buyer; provided that the Investor shall give the Company
at least 30 days prior written notice of such Sale. 

  
 -18- 








 This Section 6.1(c) shall terminate one year after the expiration or termination of the
Collaboration Agreement in accordance with its terms, if such termination occurs prior to the one year anniversary of the expiration of the Restriction Period. 

(d) Occurrence of Significant Event. The restrictions contained in Sections 6.1(b) and 6.1(c) shall be suspended and shall not apply to
or otherwise restrict the Investor’s actions in respect of the Company’s securities for so long as a Significant Event has occurred and is continuing. 

6.2 Invalid Transfers. Any sale, assignment or other transfer of Covenant Shares by the Investor or any of its
Affiliates, as applicable, contrary to the provisions of this Section 6 shall be null and void, and the transferee shall not be recognized by the Company as the holder or owner of the Covenant Shares sold, assigned, or transferred for any
purpose (including, without limitation, voting or dividend rights), unless and until the Investor or such Affiliate, as applicable, has satisfied the requirements of this Section 6 with respect to such sale. The Company, or, at the instruction
of the Company, the transfer agent of the Company, may place a legend on any certificate representing Covenant Shares stating that such shares are subject to the restrictions contained in this Agreement. Upon expiration of the Restriction Period,
the Company agrees to facilitate the timely preparation and delivery (but in no event longer than three (3) business days) of certificates representing the Covenant Shares to be sold by the Investor or any Affiliate free of any restrictive
legends and in such denominations and registered in such names as the Investor or such Affiliate may request in connection with such sale. 

6.3 Performance by Affiliates. The Investor shall remain responsible for and guarantee its Affiliates’
performance in connection with this Agreement, and shall cause each such Affiliate to comply fully with the provisions of this Agreement in connection with such performance. The Investor hereby expressly waives any requirement that the Company
exhaust any right, power or remedy, or proceed directly against such an Affiliate, for any obligation or performance hereunder, prior to proceeding directly against the Investor. 

SECTION 7 
 Registration
Rights 
 7.1 Rule 144 Reporting. With a view to making available to the Investor the benefits of certain rules and
regulations of the Commission which may permit the sale of the Shares to the public without registration, the Company agrees to use commercially reasonable efforts to: 

(a) Make and keep public information available, as those terms are understood and defined in Rule 144 promulgated under the Securities Act;

 (b) File with the Commission in a timely manner all reports and other documents required of the Company under the Exchange Act; and 

  
 -19- 








 (c) Furnish the Investor forthwith upon request (i) a written statement by the Company as to
its compliance with the public information requirements of said Rule 144, (ii) a copy of the most recent annual or quarterly report of the Company, and (iii) such other reports and documents as may be reasonably requested in availing the
Investor of any rule or regulation of the Commission permitting the sale of any such securities without registration. 
 7.2
Registration. 
 (a) If, at the end of the Restriction Period, the Shares cannot be sold without restriction
pursuant to Rule 144 promulgated under the Securities Act, then upon Investor’s written request, received by the Company on or before the 30th day after the end of the Restriction Period, the Company will use commercially reasonable efforts to
register the Shares for resale under the Securities Act on a Registration Statement on Form S-3 (the “Registration Statement”), filed within 90 days of such written request, and will use commercially reasonable efforts to
have such Registration Statement promptly declared effective by the Commission. 
 (b) The Company will use commercially
reasonable efforts to keep the Registration Statement continuously effective under the Securities Act until the earlier of (i) the date all of the Shares covered by such Registration Statement have been sold or can be sold publicly without
restriction or limitation under Rule 144 or (ii) the date that is two years following the Closing Date. 
 (c) The Investor shall
furnish to the Company such information regarding the Investor, and the distribution proposed by the Investor, as the Company may reasonably request in writing and as shall be required in connection with the Registration Statement. 

(d) The Company shall pay all fees and expenses incident to the performance of or compliance with this Section 7.2 by the Company. 

7.3 Restrictive Legend.  

(a) The certificates representing the Shares, when issued, will bear a restrictive legend in substantially the following form: 

“THE SECURITIES EVIDENCED OR CONSTITUTED HEREBY HAVE BEEN ISSUED WITHOUT REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE
“ACT”) AND MAY NOT BE SOLD, OFFERED FOR SALE, TRANSFERRED, PLEDGED OR HYPOTHECATED WITHOUT REGISTRATION UNDER THE ACT UNLESS EITHER (i) THE COMPANY HAS RECEIVED AN OPINION OF COUNSEL, IN FORM AND SUBSTANCE REASONABLY SATISFACTORY TO
THE COMPANY, TO THE EFFECT THAT REGISTRATION IS NOT REQUIRED IN CONNECTION WITH SUCH DISPOSITION OR (ii) THE SALE OF SUCH SECURITIES IS MADE PURSUANT TO RULE 144 PROMULGATED UNDER THE ACT.” 

(b) The certificates representing the Shares, when issued, shall not bear the restrictive legend set forth in Section 7.3(a):
(i) following a sale of such Shares pursuant to a registration statement covering the resale of such Shares, while such registration statement is 

  
 -20- 








 
effective under the Securities Act, (ii) following any sale of such Shares pursuant to Rule 144 promulgated under the Securities Act (“Rule 144”), (iii) if such
Shares are eligible for sale under Rule 144, without the requirement for the Company to be in compliance with the current public information required under Rule 144 as to such Shares and without volume or manner-of-sale restrictions or (iv) if
such legend is not required under applicable requirements of the Securities Act (including judicial interpretations and pronouncements issued by the staff of the Securities and Exchange Commission). The Company agrees that at such time as the
restrictive legend set forth in Section 7.3(a) is no longer required under this section, the Company will (x) no later than five (5) business days following the delivery by the Investor to the Company or the Company’s transfer
agent of a certificate representing Shares issued with such restrictive legend, deliver or cause to be delivered to the Investor a certificate representing such Shares that is free from such restrictive legend, and (y), in the event that such shares
are uncertificated, no later than five (5) business days following the delivery of a written request by the Investor to the Company to remove such restrictive legend, remove, or cause to be removed, any such restrictive legend in the
Company’s stock records. The Company may not make any notation on its records or give instructions to the Company’s transfer agent that enlarge the restrictions on transfer set forth in Sections 6.2, 7.3(a) and 7.4. 

7.4 “Lock-Up” Agreement; Confidentiality of Notices. The Investor agrees, if requested by the Company
and the managing underwriter of an IPO (but not for any subsequent offerings) (i) not to (a) offer, pledge, announce the intention to sell, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to
sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any Shares or other securities of the Company (excluding securities acquired in the public market after the IPO) or (b) enter
into any swap or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of any Shares or other securities of the Company (excluding securities acquired in the public market after the IPO), whether any
transaction described in clause (a) or (b) is to be settled by delivery of securities, in cash or otherwise, during the period beginning on the date of the filing of such registration statement with the Securities and Exchange Commission
and ending on the date specified by the Company and the managing underwriter (such period not to exceed 180 days in the case of an IPO or such other period not to exceed 18 days after the expiration of the 180-day period, as may be requested by the
Company or an underwriter to accommodate regulatory restrictions on (1) the publication or other distribution of research reports, and (2) analyst recommendations and opinions, including, but not limited to, the restrictions contained in
FINRA Rule 2711(f)(4) or NYSE Rule 472(f)(4), or any successor provisions or amendments thereto), and (ii) to execute any agreement reflecting clause (i) above as may be requested by the Company or the managing underwriters at the time of
such offering. 
 The Company may impose stop-transfer instructions with respect to the Registrable Shares or other securities
subject to the foregoing restriction until the end of such “lock-up” period. 
 As a condition to the obligation of the Investor
under this Section 7.4, any “lock-up” obligation of the Investor under this Section 7.4, and any agreement entered into by the Investor as a result of its obligations under this Section 7.4, shall allow for periodic early
releases of portions of the securities subject to such “lock-up” obligations, which may be conditioned upon the trading price of the Company’s Common Stock. 

  
 -21- 








 If the Investor receives any written notice from the Company regarding the Company’s plans
to file a Registration Statement, the Investor shall treat such notice confidentially and shall not disclose such information to any person other than as necessary to exercise its rights under this Agreement. 

SECTION 8 
 Conversion
to Series E Preferred Stock Financing 
 In the event that the IPO has not occurred prior to December 15, 2015, then this Agreement
shall be automatically, and without further action of either party hereto, be amended and restated in in its entirety to read in the form attached hereto as Exhibit B, with the Closing to occur on or before December 31, 2015 (subject to the
terms and conditions set forth therein). 
 SECTION 9 

Indemnification 
 Each
party (an “Indemnifying Party”) hereby indemnifies and holds harmless the other party, such other party’s respective officers, directors, employees, consultants, representatives and advisers, and any and all Affiliates
(as defined in the Series E Preferred Stock Purchase Agreement, by and between the Company and the Investor, of even date herewith (the “Series E Preferred Stock Purchase Agreement”)) of the foregoing (each of the foregoing,
an “Indemnified Party”) from and against all losses, liabilities, costs, damages and expense (including reasonable legal fees and expenses) (collectively, “Losses”) suffered or incurred by any such
Indemnified Party to the extent arising from, connected with or related to (i) breach of any representation or warranty of such Indemnifying Party in this Agreement; and (ii) breach of any covenant or undertaking of any Indemnifying Party
in this Agreement. If an event or omission (including, without limitation, any claim asserted or action or proceeding commenced by a third party) occurs which an Indemnified Party asserts to be an indemnifiable event pursuant to this Section 8,
the Indemnified Party will provide written notice to the Indemnifying Party, setting forth the nature of the claim and the basis for indemnification under this Agreement. The Indemnified Party will give such written notice to the Indemnifying Party
immediately after it becomes aware of the existence of any such event or occurrence. Such notice will be a condition precedent to any obligation of the Indemnifying Party to act under this Agreement but will not relieve it of its obligations under
the indemnity except to the extent that the failure to provide prompt notice as provided in this Agreement prejudices the Indemnifying Party with respect to the transactions contemplated by this Agreement and to the defense of the liability. In case
any such action is brought by a third party against any Indemnified Party and it notifies the Indemnifying Party of the commencement thereof, the Indemnifying Party will be entitled to participate therein and, to the extent that it wishes, to assume
the defense and settlement thereof with counsel reasonably selected by it and, after notice from the Indemnifying Party to the Indemnified Party of such election so to assume the defense and settlement thereof, the Indemnifying Party will not be
liable to the Indemnified Party for any legal expenses of other counsel or any other expenses subsequently incurred by such Indemnified Party in connection with the defense thereof, provided, however, that an Indemnified Party shall have the right
to employ separate counsel at the expense of the Indemnifying Party if (i) the employment thereof has been 

  
 -22- 








 
specifically authorized in writing by the Indemnifying Party; or (ii) representation of both parties by the same counsel would be inappropriate due to actual or potential conflicts of
interests between such parties (which such judgment shall be made in good faith after consultation with counsel). The Indemnified Party agrees to cooperate fully with (and to provide all relevant documents and records and make all relevant personnel
available to) the Indemnifying Party and its counsel, as reasonably requested, in the defense of any such asserted claim at no additional cost to the Indemnifying Party. No Indemnifying Party will consent to the entry of any judgment or enter into
any settlement with respect to any such asserted claim without the prior written consent of the Indemnified Party, not to be unreasonably withheld or delayed, (a) if such judgment or settlement does not include as an unconditional term thereof
the giving by each claimant or plaintiff to each Indemnified Party of a release from all liability in respect to such claim or (b) if, as a result of such consent or settlement, injunctive or other equitable relief would be imposed against the
Indemnified Party or such judgment or settlement could materially and adversely affect the business, operations or assets of the Indemnified Party. No Indemnified Party will consent to the entry of any judgment or enter into any settlement with
respect to any such asserted claim without the prior written consent of the Indemnifying Party, not to be unreasonably withheld or delayed. If an Indemnifying Party makes a payment with respect to any claim under the representations or warranties
set forth herein and the Indemnified Party subsequently receives from a third party or under the terms of any insurance policy a sum in respect of the same claim, the receiving party will repay to the other party such amount that is equal to the sum
subsequently received. 
 SECTION 10 

Miscellaneous 

10.1 Governing Law. This Agreement shall be governed in all respects by the laws of the State of Delaware (without
reference to the conflicts of law provisions thereof). 
 10.2 Survival. The representations,
warranties, covenants and agreements made herein shall survive any investigation made by the Investor and the Closing. 
 10.3
Successors, Assigns. Except as otherwise provided herein, the provisions hereof shall inure to the benefit of, and be binding upon, the successors, assigns, heirs, executors and administrators of the parties hereto. This Agreement may
not be assigned by either party without the prior written consent of the other; except that either party may assign this Agreement to an Affiliate (as defined in Series E Preferred Stock Purchase Agreement) of such party or to any third party that
acquires all or substantially all of such party’s business, whether by merger, sale of assets or otherwise. 
 10.4
Notices. All notices and other communications required or permitted hereunder shall be in writing and shall be sent by facsimile (receipt confirmed) or mailed by registered or certified mail, postage prepaid, return receipt requested,
or otherwise delivered by hand or by messenger, addressed 

  
 -23- 








 if to the Investor, at the following address: 

Novartis Institutes for BioMedical Research, Inc. 

250 Massachusetts Avenue 

Cambridge, MA 02139 
 Attention:
General Counsel 
 Facsimile: (617) 871-5786 

with a copy (which shall not constitute notice) to: 

Kaye Scholer LLP 
 250 West 55th Street 
 New York, New York 10019-9710 

Attention: Thomas Yadlon 

Facsimile: (212) 836-6567 

if to the Company, at the following address: 

Aduro Biotech, Inc. 
 626 Bancroft
Way #3C 
 Berkeley, CA 94710 

Attention: President 
 Facsimile:
(510) 848-5614 
 with a copy (which shall not constitute notice) to: 

Cooley LLP 
 3175 Hanover Street

 Palo Alto, California 94304 

Attention: Michael Tenta 

Facsimile: (650) 849-7400 
 or at such other
address as one party shall have furnished to the other party in writing. If notice is provided by facsimile, it shall be deemed to be given one (1) business day after transmission (with receipt of appropriate confirmation). If notice is
provided by U.S. mail, notice shall be deemed to be given four (4) days after proper deposit in a U.S. mailbox, postage prepaid, and properly addressed. If notice is provided by a messenger service that guarantees “next business day”
delivery, it shall be deemed effective one (1) business day after deposit with such messenger service. 
 10.5
Expenses. Each of the Company and the Investor shall bear its own expenses and legal fees incurred on its behalf with respect to this Agreement and the transactions contemplated hereby. 

10.6 Confidentiality.  

(a) Subject to the other provisions of this Section 10.6, the existence of this Agreement and the terms and conditions of this Agreement
(collectively, the “Confidential 

  
 -24- 








 
Information”) will be maintained in confidence and otherwise safeguarded by the parties to this Agreement. Subject to the other provisions of this
Section 10.6, each party shall hold as confidential such Confidential Information in the same manner and with the same protection as such party maintains its own confidential information. Subject to the other provisions of this
Section 10.6, a party may only disclose Confidential Information to its employees, representatives, agents, sublicensees, subcontractors, consultants and advisers and its affiliates to the extent reasonably necessary for the purposes of, and
for those matters undertaken pursuant to, this Agreement; provided that such persons are bound to maintain the confidentiality of the Confidential Information in a manner consistent with the confidentiality provisions of this Agreement. 

(b) The obligations under this Section 10.6 shall not apply to any information to the extent the disclosing party can demonstrate by
competent evidence that such information is (at the time of disclosure) or becomes (after the time of disclosure) known to the public or part of the public domain through no breach of this Agreement by such party or its affiliates. 

(c) In addition to disclosures allowed under Section 10.6(b), each party may disclose Confidential Information solely to the extent such
disclosure is necessary in the following instances: (i) complying with applicable law, court orders or governmental regulations, including rules of self-regulatory organizations and Securities and Exchange Commission filing and disclosure
requirements or (ii) to potential or actual investors or acquirers as may be necessary in connection with their evaluation of a potential or actual investment or acquisition; provided that such persons shall be subject to obligations of
confidentiality and non-use at least as protective as those set forth in this Section 10.6. 
 (d) In the event a party is required to
disclose Confidential Information by law, applicable court order or governmental regulation or in connection with bona fide legal process, such disclosure shall not be a breach of this Agreement; provided that such party (i) informs the other
party as soon as reasonably practicable of the required disclosure; (ii) limits the disclosure to that which is legally required to be disclosed; and (iii) at the other party’s request and expense, assists in an attempt to object to
or limit the required disclosure. 
 (e) Either party may disclose the existence and terms of this Agreement in confidence to its attorneys
and advisors, and to potential acquirers (and their respective professional attorneys and advisors), in connection with a potential merger, acquisition or reorganization and to existing and potential investors or lenders of such party, as part of
their due diligence investigations, or to existing and potential licensees or sublicensees or to permitted assignees, in each case under an agreement to keep the terms of confidentiality and non-use substantially no less rigorous than the terms
contained in this Agreement and to use such information solely for the purpose permitted pursuant to this Section 10.6(e). 

10.7 Finder’s Fees. Each of the Company and the Investor shall indemnify and hold the other harmless from any
liability for any commission or compensation in the nature of a finder’s fee, placement fee or underwriter’s discount (including the costs, expenses and legal fees of defending against such liability) for which the Company or the Investor,
or any of its respective partners, employees, or representatives, as the case may be, is responsible. 

  
 -25- 








 10.8 Counterparts. This Agreement may be executed in counterparts,
each of which shall be enforceable against the party actually executing the counterpart, and all of which together shall constitute one instrument. 

10.9 Severability. In the event that any provision of this Agreement becomes or is declared by a court of
competent jurisdiction to be illegal, unenforceable or void, this Agreement shall continue in full force and effect without said provision; provided that no such severability shall be effective if it materially changes the economic benefit of this
Agreement to any party. 
 10.10 Entire Agreement. This Agreement, including the exhibits and
schedule attached hereto, constitute the full and entire understanding and agreement among the parties with regard to the subjects hereof and thereof. No party shall be liable or bound to any other party in any manner with regard to the subjects
hereof or thereof by any warranties, representations or covenants except as specifically set forth herein or therein. 

10.11 Waiver. The failure of either party to assert a right hereunder or to insist upon compliance with any term
or condition of this Agreement shall not constitute a waiver of that right or excuse a similar subsequent failure to perform any such term or condition by the other party. None of the terms, covenants and conditions of this Agreement can be waived
except by the written consent of the party waiving compliance. 
 10.12 Termination. This Agreement shall
terminate automatically if the Collaboration Agreement is terminated pursuant to its terms prior to the consummation of the Closing. 
 [This
space left intentionally blank. Signature page follows.] 

  
 -26- 








 IN WITNESS WHEREOF, the parties have executed this Common Stock Purchase Agreement as of the date
first set forth above. 
  

			
	COMPANY:
	
	ADURO BIOTECH, INC.
	
	 /s/ Stephen T. Isaacs

	By:		Stephen T. Isaacs
			President and Chief Executive Officer


 SIGNATURE PAGE TO ADURO BIOTECH, INC. 

COMMON STOCK PURCHASE AGREEMENT 







 IN WITNESS WHEREOF, the parties have executed this Common Stock Purchase Agreement as of the date
first set forth above. 
  

			
	INVESTOR:
	
	 NOVARTIS INSTITUTES FOR
 BIOMEDICAL
RESEARCH, INC.

	
	 /s/ Scott A. Brown

	By:		Scott A. Brown
			VP, General Counsel


 SIGNATURE PAGE TO ADURO BIOTECH, INC. 

COMMON STOCK PURCHASE AGREEMENT 







 Schedule A 

The Investor is an institutional “accredited investor” as defined in Rule 501(a) of Regulation D of the Securities Act. 







 EXHIBIT A 

Confidential Information and Inventions Assignment Agreement 







 Aduro BioTech, Inc. 

Proprietary Information And Inventions Agreement 

In consideration of my employment or continued employment by Aduro BioTech, Inc. (the “Company”), and the compensation now and hereafter paid to me,
I hereby agree as follows: 
 1. Recognition of Company’s Rights: Nondisclosure. At all times during the term of my employment and thereafter, I
will hold in strictest confidence and will not disclose, use, lecture upon or publish any of the Company’s Proprietary Information (defined below), except as such disclosure, use or publication may be required in connection with my work for the
Company, or unless the Board of Directors of the Company expressly authorizes such in writing. I hereby assign to the Company any rights I may have or acquire in such Proprietary Information and recognize that all Proprietary Information shall be
the sole property of the Company and its assigns and that the Company and its assigns shall be the sole owner of all patent rights, copyrights, mask work rights, trade secret rights and all other rights throughout the world (collectively,
“Proprietary Rights”) in connection therewith. 
 The term “Proprietary Information” shall mean trade secrets, confidential knowledge,
data or any other proprietary information of the Company. By way of illustration but not limitation, “Proprietary Information” includes (a) inventions, mask works, trade secrets, ideas, processes, formulas, source and object codes,
data, programs, other works of authorship, cell lines, know- how, improvements, discoveries, developments, designs and techniques (hereinafter collectively referred to as “Inventions”); and
(b) information regarding plans for research, development, new products, marketing and selling, business plans, budgets and unpublished financial statements, licenses, prices and costs, suppliers and customers; and information regarding the
skills and compensation of other employees of the Company. 
 2. Third Party Information. I understand, in addition, that the Company has received
and in the future will receive from third parties confidential or proprietary information (“Third Party Information”) subject to a duty on the Company’s part to maintain the confidentiality of such information and to use it only for
certain limited purposes. During the term of my employment and thereafter, I will hold Third Party Information in the strictest confidence and will not disclose (to anyone other than Company personnel who need to know such information in connection
with their work for the Company) or use, except in connection with my work for the Company, Third Party Information unless expressly authorized by an officer of the Company in writing. 

 

	3.	Assignment of Inventions. 

 (a) I hereby assign to the Company all my right, title and
interest in and to any and all Inventions (and all Proprietary Rights with respect thereto) whether or not patentable or registrable under copyright or similar statutes, made or conceived or reduced to practice or learned by me, either alone or
jointly with others, during the period of my employment with the Company. 







 (b) I acknowledge that all original works of authorship which are made by me (solely or jointly
with others) within the scope of my employment and which are protectable by copyright are “works made for hire,” as that term is defined in the United States Copyright Act (17 U.S.C., Section 101). Inventions assigned to or as
directed by the Company by this paragraph 3 are hereinafter referred to as “Company Inventions.” 
 4. Enforcement of Proprietary Rights. I
will assist the Company in every proper way to obtain and from time to time enforce United States and foreign Proprietary Rights relating to Company Inventions in any and all countries. To that end I will execute, verify and deliver such documents
and perform such other acts (including appearances as a witness) as the Company may reasonably request for use in applying for, obtaining, perfecting, evidencing, sustaining and enforcing such Proprietary Rights and the assignment thereof. In
addition, I will execute, verify and deliver assignments of such Proprietary Rights to the Company or its designee. My obligation to assist the Company with respect to Proprietary Rights relating to such Company Inventions in any and all countries
shall continue beyond the termination of my employment, but the Company shall compensate me at a reasonable rate after my termination for the time actually spent by me at the Company’s request on such assistance. 

In the event the Company is unable for any reason, after reasonable effort, to secure my signature on any document needed in connection with the actions
specified in the preceding paragraph, I hereby irrevocably designate and appoint the Company and its duly authorized officers and agents as my agent and attorney in fact, to act for and in my behalf to execute, verify and file any such documents and
to do all other lawfully permitted acts to further the purposes of the preceding paragraph thereon with the same legal force and effect as if executed by me. I hereby waive and quitclaim to the Company any and all claims, of any nature whatsoever,
which I now or may hereafter have for infringement of any Proprietary Rights assigned hereunder to the Company. 
 5. Obligation to Keep Company Informed.
During the period of my employment, I will promptly disclose to the Company fully and in writing and will hold in trust for the sole right and benefit of the Company any and all Inventions. In addition, after termination of my employment, I will
disclose all patent applications filed by me within a year after termination of employment. 
 6. Prior Inventions. Inventions, if any, patented or
unpatented, which I made prior to the commencement of my employment with the Company are excluded from the scope of this Agreement. To preclude any possible uncertainty, I have set forth on Exhibit A attached hereto a complete list of all Inventions
that I have, alone or jointly with others, conceived, developed or reduced to practice or caused to be conceived, developed or reduced to practice prior to commencement of my employment with the Company, that I consider to be my property or the
property of third parties and that I wish to have excluded from the scope of this Agreement. If disclosure of any such Invention on Exhibit A would cause me to violate any prior confidentiality agreement, I understand that I am not to list such
Inventions in Exhibit A but am to inform the Company that all Inventions have been listed for that reason. 
 7. Additional Activities. I agree that
during the period of my employment by the Company I will not, without the Company’s express written consent, engage in any employment or business activity other than for the Company except as noted on my Employment Agreement,








 
and for the period of my employment by the Company and for two (2) years after the date of termination of my employment by the Company I will not induce any employee of the Company to leave
the employ of the Company per the terms of my Employment Agreement. 
 8. No Improper Use of Materials. During my employment by the Company I will
not improperly use or disclose any confidential information or trade secrets, if any, of any former employer or any other person to whom I have an obligation of confidentiality, and I will not bring onto the premises of the Company any unpublished
documents or any property belonging to any former employer or any other person to whom I have an obligation of confidentiality unless consented to in writing by that former employer or person. 

9. No Conflicting Obligation. I represent that my performance of all the terms of this Agreement and as an employee of the Company does not and will
not breach any agreement to keep in confidence information acquired by me in confidence or in trust prior to my employment by the Company. I have not entered into, and I agree I will not enter into, any agreement either written or oral in conflict
herewith. 
 10. Return of Company Documents. When I leave the employ ofthe Company, I will deliver to the Company all drawings, notes, memoranda,
specifications, devices, formulas, molecules, cells and documents, together with all copies thereof, and any other material containing or disclosing any Company Inventions, Third Party Information or Proprietary Information of the Company. I further
agree that any property situated on the Company’s premises and owned by the Company, including disks and other storage media, filing cabinets or other work areas, is subject to inspection by Company personnel at any time with or without notice.
Prior to leaving, I will cooperate with the Company in completing and signing the Company’s termination statement for technical and management personnel. 

11. Equal and Equitable Remedies. Because my services ate personal and unique and because I may have access to and become acquainted with the
Proprietary Information ofthe Company, the Company shall have the right to enforce this Agreement and any of its provisions by injunction, specific performance or other equitable relief, without bond, without prejudice to any other rights and
remedies that the Company may have for a breach of this Agreement. 
 12. Notices. Any notices required or permitted hereunder shall be given to the
appropriate party at the address specified below or at such other address as the party shall specify in writing. Such notice shall be deemed given upon personal delivery to the appropriate address or if sent by certified or registered mail, three
days after the date of mailing. 
  

	13.	General Provisions. 

  

	(a)	Governing Law. This Agreement will be governed by and construed according to the laws of the State of California. 


(b) Entire Agreement. This Agreement sets forth the entire agreement and understanding between the Company and me relating to the subject matter hereof
and supersedes and merges all prior discussions between us. No modification of or amendment to this Agreement, nor any waiver of any rights under this Agreement, will be effective unless in writing signed by the party to be charged. Any subsequent
change or changes in my duties, 







 
salary or compensation will not affect the validity or scope of this Agreement. As used in this Agreement, the period of my employment includes any time during which I may be retained by the
Company as a consultant. 
 (c) Severability. If one or more of the provisions in this Agreement are deemed unenforceable by law, then the remaining
provisions will continue in full force and effect. 
 (d) Successors and Assigns. This Agreement will be binding upon my heirs, executors,
administrators and other legal representatives and will be for the benefit of the Company, its successors and its assigns. 
 (e) Survival. The
provisions of this Agreement shall survive the termination of my employment and the assignment of this Agreement by the Company to any successor in interest or other assignee. 

(f) Employment. I agree and understand that nothing in this Agreement shall confer any right with respect to continuation of employment by the Company,
nor shall it interfere in any way with my right or the Company’s right to terminate my employment at any time, with or without cause. 
 (g)
Waiver. No waiver by the Company of any breach of this Agreement shall be a waiver of any preceding or succeeding breach. No waiver by the Company of any right under this Agreement shall be construed as a waiver of any other right. The
Company shall not be required to give notice to enforce strict adherence to all terms of this Agreement. 
 (h) Effectiveness. This Agreement shall
be effective as of the first day of my employment with the Company. 
 I UNDERSTAND THAT THIS AGREEMENT AFFECTS MY RIGHTS TO INVENTIONS MAKE DURING MY
EMPLOYMENT, AND RESTRICTS MY RIGHT TO DISCLOSE OR USE THE COMPANY’S PROPRIETARY INFORMATION DURING OR SUBSEQUENT TO MY EMPLOYMENT. 

[Continued on next page] 







 I HAVE READ THIS AGREEMENT CAREFULLY AND UNDERSTAND ITS TERMS. I HAVE COMPLETELY FILLED OUT EXHIBIT A TO THIS
AGREEMENT. 
 Dated as of                     , 2012

 (Date of First Employment) 
  

							
		 		 		 	  

		 		 		 	Signature of Employee
				
		 		 		 	  

		 		 		 	Printed Name of Employee
				
		 		 		 	  

		 		 		 	Address of Employee
			
	ACCEPTED AND AGREED TO:	 		 	
			
	 Aduro BioTech, Inc.
  
	 		 	
	By:    	 	  
	 		 	
		 	Stephen Isaacs, Chairman & CEO	 		 	








 EXHIBIT B 

Form of Preferred Stock Purchase Agreement 







 EXHIBIT B 

ADURO BIOTECH, INC. 

SERIES E PREFERRED STOCK PURCHASE AGREEMENT (SECOND TRANCHE) 

THIS SERIES E PREFERRED STOCK PURCHASE AGREEMENT (SECOND TRANCHE) (the “Agreement”) is made as of March 12, 2015
(the “Execution Date”) by and between Aduro Biotech, Inc., a Delaware corporation (the “Company”), and Novartis Institutes for BioMedical Research, Inc., a Delaware corporation (the
“Investor”). 
 RECITALS 

WHEREAS, the Company and the Investor are party to that certain Series E Purchase Agreement, made as of March 12, 2015 (the
“First Tranche Purchase Agreement”), pursuant to which the Company has agreed to issue to the Investor, and the Investor has agreed to purchase from the Company, 2,361,029 shares of Series E Preferred Stock, par value $0.0001
per share (the “Series E Preferred”), on the terms and conditions set forth therein; and 
 WHEREAS, pursuant
to terms set forth in this Agreement the Company desires to sell to the Investor, and the Investor desires to purchase from the Company, additional shares of Series E Preferred. 

NOW, THEREFORE, in consideration of the premises and mutual covenants herein contained, and for other good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows: 
 SECTION 1 

Purchase and Sale of Shares 

1.1 Authorization. The Company has, or before Closing (as defined in Section 1.3) will have, duly authorized the sale and
issuance, pursuant to the terms of this Agreement, of 2,361,029 shares of Series E Preferred, having the rights, privileges, preferences and restrictions set forth in the Company’s Certificate of Incorporation. 

1.2 Sale of Shares. Subject to the terms and conditions of this Agreement, the Company will sell and issue to the Investor, and
the Investor will purchase, an aggregate of 2,361,029 shares of Series E Preferred for the cash purchase price of $10.5886 per share (the “Purchase Price”). The shares of Series E Preferred sold under this Agreement are
collectively referred to as the “Shares.” 
 1.3 Closing. The purchase and sale of the Shares shall
take place at a closing (the “Closing”) to be held at the offices of Cooley LLP, 3175 Hanover Street, Palo Alto, California 94304-1130, on a date following the satisfaction or waiver of each of the conditions set forth in
Sections 4 and 5 hereof (other than those conditions that are to be satisfied at the Closing, but subject to satisfaction or waiver of such conditions) to be mutually agreed by the parties and be no later than 







 
December 31, 2015, unless such conditions (other than those conditions that are to be satisfied at the Closing) are not satisfied on or prior to December 30, 2015, in which case the
Closing will take place on second business day following the satisfaction or waiver of such conditions (other than those conditions that are to be satisfied at the Closing, but subject to satisfaction or waiver of such conditions) (the
“Closing Date”). At the Closing, the Company will deliver or cause to be delivered to the Investor a certificate or certificates representing the Shares that the Investor is purchasing and, concurrently, the Investor shall
purchase the Shares at a price per share equal to the Purchase Price by wire transfer in accordance with the Company’s instructions, which shall be provided in writing no later than two business days prior to the Closing Date. 

SECTION 2 

Representations and Warranties of the Company 

Except as set forth on the Schedule of Exceptions delivered by the Company to the Investor on the date hereof, the Company hereby represents
and warrants the following as of the date hereof and as of the Closing Date (except for the representations and warranties that speak as of a specific date, which shall be made as of such date). For purposes of these representations and warranties
(other than those set forth in Sections 2.2, 2.4 and 2.6) the term “Company” includes any subsidiaries of the Company. 
 2.1
Organization and Good Standing and Qualifications. The Company is a corporation duly organized, validly existing and in good standing under the laws of the State of Delaware and has full corporate power and authority to conduct its
business as presently conducted and as proposed to be conducted by it. The Company is duly qualified to do business as a foreign corporation in California and is in good standing under the laws of such State. The Company is not required to be
qualified to do business as a foreign corporation in any other jurisdiction in which the failure so to qualify would have a material adverse effect on the business, prospects, assets or condition (financial or otherwise) of the Company (a
“Company Material Adverse Effect”). The Company has furnished to the Investor complete and accurate copies of its Certificate of Incorporation and By-laws, each as amended to date and presently in effect. The Company has at
all times complied with all provisions of its Certificate of Incorporation and By-laws and is not in default under, or in violation of, any such provision. The Company is not, and has never been, a “shell company,” as described in
paragraphs (i)(1)(i) and (ii) of Rule 144 promulgated under the Securities Act of 1933, as amended (the “Securities Act”). 

2.2 Subsidiaries, Etc. Except as set forth in Section 2.2 of the Schedule of Exceptions, the Company has no subsidiaries and
does not own or control, directly or indirectly, any shares of capital stock of any other corporation or any interest in any partnership, limited liability company, joint venture or other non-corporate business enterprise. 

2.3 Authorization. The execution, delivery and performance by the Company of this Agreement, and the consummation by the Company
of the transactions contemplated hereby, have been duly authorized by all necessary corporate action. This Agreement has been duly executed and 

  
 -2- 








 
delivered by the Company and constitutes a valid and binding obligation of the Company enforceable against the Company in accordance with its respective terms. The execution and delivery of this
Agreement, the consummation of the transactions contemplated hereby and the compliance with the provisions of this Agreement by the Company will not (a) conflict with or violate any provision of the Certificate of Incorporation or By-laws of
the Company, (b) conflict with, result in a breach of, constitute (with or without due notice or lapse of time or both) a default under, result in the acceleration of obligations under, create in any party the right to accelerate, terminate,
modify or cancel, or require any notice, consent or waiver under, any contract, lease, sublease, license, sublicense, franchise, permit, indenture, agreement or mortgage for borrowed money, instrument of indebtedness, Security Interest (as defined
below) or other arrangement to which the Company is a party or by which the Company is bound or to which its assets are subject, (c) result in the imposition of any Security Interest upon any assets of the Company or (d) violate any order,
writ, injunction, decree, statute, rule or regulation applicable to the Company or any of its properties or assets. For purposes of this Agreement, “Security Interest” means any mortgage, pledge, security interest,
encumbrance, charge or other lien (whether arising by contract or by operation of law). 
 2.4 Valid Issuance of Shares. The
issuance, sale and delivery of the Shares in accordance with this Agreement, and the issuance and delivery of the shares of Common Stock issuable upon conversion of the Shares, have been, or will be on or prior to the Closing, duly authorized by all
necessary corporate action on the part of the Company, and all such shares have been duly reserved for issuance. The Shares when so issued, sold and delivered against payment therefor in accordance with the provisions of this Agreement, and the
shares of Common Stock issuable upon conversion of the Shares, when issued upon such conversion, will be duly and validly issued, fully paid and nonassessable, and free of restrictions on transfer other than restrictions imposed or created under
this Agreement, by applicable law, or by the Investor. 
 2.5 [Intentionally omitted.] 

2.6 Capitalization. 

(a) The authorized capital stock of the Company as of the date of this Agreement consists of (i) 85,000,000 shares of Common Stock,
$0.0001 par value per share, of which 589,214 shares are issued and outstanding and none are held in the treasury of the Company, and (ii) 69,716,345 shares of Preferred Stock, $0.0001 par value per share, of which (A) 161,843 shares have
been designated as Series A Preferred, all of which are issued and outstanding, (B) 3,393,666 shares have been designated as Series A-1 Preferred, 3,369,431 of which are issued and outstanding, (C) 21,525,480 shares have been designated as
Series B Preferred, 21,441,709 of which are issued and outstanding, (D) 25,623,183 shares have been designated as Series C Preferred, all of which are issued and outstanding and (E) 19,012,173 shares have been designated as Series D
Preferred, all of which are issued and outstanding. Since the Execution Date, the Company has not issued any shares of Series E Preferred other than the 2,361,029 shares of Series E Preferred that are subject to issuance pursuant to the First
Tranche Purchase Agreement. 

  
 -3- 








 (c) Section 2.6(b) of the Schedule of Exceptions includes a complete and accurate list, as
of the date of this Agreement, of the holders of capital stock of the Company, showing the number of shares of capital stock, and the class or series of such shares, held by each stockholder and (for shares other than Common Stock) the number of
shares of Common Stock (if any) into which such shares are convertible, immediately prior to the Closing. Section 2.6(b) of the Schedule of Exceptions also indicates all outstanding shares of Common Stock that constitute restricted stock or
that are otherwise subject to a repurchase or redemption right, indicating the name of the applicable stockholder, the vesting schedule (including any acceleration provisions with respect thereto), and the repurchase price payable by the Company.
All of the issued and outstanding shares of capital stock of the Company have been duly authorized and validly issued and are fully paid and nonassessable. All of the issued and outstanding shares of capital stock of the Company have been offered,
issued and sold by the Company in compliance with all applicable federal and state securities laws. 
 (c) Section 2.6(c) of the
Schedule of Exceptions includes a complete and accurate list, as of the date of this Agreement of: (i) all stock option plans and other stock or equity- related plans of the Company (the “Company Stock Plans”),
indicating for each Company Stock Plan the number of shares of Common Stock issued to date under such Plan, the number of shares subject to outstanding options under such Plan and the number of shares reserved for future issuance under such Plan;
(ii) all holders of outstanding options to purchase shares of Common Stock (“Company Stock Options”), indicating with respect to each Company Stock Option the Company Stock Plan under which it was granted, the number of
shares of Common Stock subject to such Company Stock Option, the exercise price, the date of grant and the vesting schedule (including any acceleration provisions with respect thereto); and (iii) all holders of warrants or other rights (other
than Company Stock Options and convertible preferred stock) to purchase or acquire shares of capital stock of the Company (collectively, the “Company Warrants”), indicating with respect to each Company Warrant the agreement
or other document under which it was granted, the number of shares of capital stock, and the class or series of such shares, subject to such Company Warrant, the exercise price, the date of issuance and the expiration date thereof. The Company has
furnished to the Investor complete and accurate copies of all Company Stock Plans, forms of all stock option agreements evidencing Company Stock Options and all Company Warrants. All of the shares of capital stock of the Company subject to Company
Stock Options and Company Warrants will be, upon issuance pursuant to the exercise of such instruments, duly authorized, validly issued, fully paid and nonassessable. 

(d) Except as set forth in Section 2.6(c) and Section 2.6(d) of the Schedule of Exceptions, (i) no subscription, warrant,
option, convertible security or other right (contingent or otherwise) to purchase or acquire any shares of capital stock of the Company is authorized or outstanding, (ii) the Company has no obligation (contingent or otherwise) to issue any
subscription, warrant, option, convertible security or other such right, or to issue or distribute to holders of any shares of its capital stock any evidences of indebtedness or assets of the Company, (iii) the Company has no obligation
(contingent or otherwise) to purchase, redeem or otherwise acquire any shares of its capital stock or any interest therein or to pay any dividend or to make any other distribution in respect thereof, and (iv) there are no outstanding or
authorized stock appreciation, phantom stock or similar rights with respect to the Company. 

  
 -4- 








 (e) Except as set forth in Section 2.6(e) of the Schedule of Exceptions, there is no
agreement, written or oral, between the Company and any holders of its securities, or, to the best of the Company’s knowledge, among any holder of its securities, relating to the sale or transfer (including without limitation agreements
relating to rights of first refusal, co sale rights or “drag along” rights), registration under the Securities Act, or voting, of the capital stock of the Company. 

2.7 Financial Statements. The Company has furnished to the Investor a complete and accurate copy of (a) the audited balance
sheet of the Company at December 31, 2014 (the “Balance Sheet Date”) and the related audited statement of operations for the fiscal year then ended (collectively, the “Financial Statements”). The
Financial Statements are in accordance with the books and records of the Company and present fairly the financial condition and results of operations of the Company, at the dates and for the periods indicated. 

2.8 Material Adverse Change. Except as set forth in Section 2.8 of the Schedule of Exceptions, since the Balance Sheet
Date, there has not been: 
 (a) any change in the assets, liabilities, financial condition or operating results of the Company from that
reflected in the Financial Statements, except changes in the ordinary course of business that have not caused, in the aggregate, a Company Material Adverse Effect; 

(b) any damage, destruction or loss, whether or not covered by insurance, that would have a Company Material Adverse Effect; 

(c) any waiver or compromise by the Company of a valuable right or of a material debt owed to it; 

(d) any satisfaction or discharge of any lien, claim, or encumbrance or payment of any obligation by the Company, except in the ordinary
course of business and the satisfaction or discharge of which would not have a Company Material Adverse Effect; 
 (e) any material change
to a material contract or agreement by which the Company or any of its assets is bound or subject; 
 (f) any material change in any
compensation arrangement or agreement with any employee, officer, director or stockholder; 
 (g) any resignation or termination of
employment of any officer or Key Employee of the Company; 
 (h) any mortgage, pledge, transfer of a security interest in, or lien, created
by the Company, with respect to any of its material properties or assets, except liens for taxes not yet due or payable and liens that arise in the ordinary course of business and do not materially impair the Company’s ownership or use of such
property or assets; 

  
 -5- 








 (i) any loans or guarantees made by the Company to or for the benefit of its employees, officers
or directors, or any members of their immediate families, other than travel advances and other advances made in the ordinary course of its business; 

(j) any declaration, setting aside or payment or other distribution in respect of any of the Company’s capital stock, or any direct or
indirect redemption, purchase, or other acquisition of any of such stock by the Company; 
 (k) any sale, assignment or transfer of any
Company Intellectual Property that could reasonably be expected to result in a Company Material Adverse Effect; 
 (l) receipt of notice
that there has been a loss of, or material order cancellation by, any major customer of the Company; 
 (m) to the Company’s knowledge,
any other event or condition of any character, other than events affecting the economy or the Company’s industry generally, that could reasonably be expected to result in a Company Material Adverse Effect; or 

(n) any arrangement or commitment by the Company to do any of the things described in this Section 2.8. 

2.9 No Undisclosed Liabilities. Except as set forth in Section 2.9 of the Schedule of Exceptions, the Company does not have
any liability (whether known or unknown and whether absolute or contingent), except for (a) liabilities shown expressly, or included in amounts shown, on the Balance Sheet, (b) liabilities less than $250,000 on an individual basis, which
have arisen since the Balance Sheet Date in the ordinary course of business and which are similar in nature and amount to the liabilities which arose during the comparable period of time in the immediately preceding fiscal period and
(c) contractual liabilities incurred in the ordinary course of business which are not required by GAAP to be reflected on a balance sheet and which would not, either individually or in the aggregate, have or result in a Company Material Adverse
Effect. 
 2.10 Governmental Consents. No consent, approval, order or authorization of, or registration, qualification,
designation, declaration or filing with, any court, arbitrational tribunal, administrative agency or commission or other governmental or regulatory authority or agency (each of the foregoing is hereafter referred to as a “Governmental
Entity”) is required on the part of the Company in connection with the offer, issuance, sale and delivery of the Shares, or the issuance and delivery of the shares of Common Stock issuable upon conversion of the Shares, as contemplated
by this Agreement, except such filings as shall have been made prior to and shall be effective on and as of the Closing and such filings required to be made after the Closing under applicable federal and state securities laws, all of which filings
are specified in the Schedule of Exceptions. Based on the representations made by the Investor in Section 3 of this Agreement, the offer and sale of the Shares to the Investor will be in compliance with applicable federal and state securities
laws. 

  
 -6- 








 2.11 Actions Pending. There is no action, suit or proceeding, or governmental
inquiry or investigation, pending, or, to the best of the Company’s knowledge, any basis therefor or threat thereof, against the Company or any officer, director or Key Employee of the Company, which questions the validity of this Agreement or
the right of the Company to enter into such agreement or to consummate the transactions contemplated hereby. There is no litigation pending, or, to the best of the Company’s knowledge, any basis therefor or threat thereof, against the Company
or any of its employees by reason of the past employment relationships of any of the employees, the proposed activities of the Company, or negotiations by the Company with possible investors in the Company. The Company is not subject to any
outstanding judgment, order or decree. 
 2.12 Foreign Corrupt Practices Act, OFAC and Anti-Money Laundering. 

(a) None of the Company, its subsidiaries or, to the knowledge of the Company, any of the Company’s directors, officers, employees or
agents has taken any action, directly or indirectly, that would result in a violation by such persons of the Foreign Corrupt Practices Act of 1977, as amended, and the rules and regulations thereunder (the “FCPA”), including,
without limitation, making use of the mails or any means or instrumentality of interstate commerce corruptly in furtherance of an offer, payment, promise to pay or authorization of the payment of any money, or other property, gift, promise to give,
or authorization of the giving of anything of value to any “foreign official” (as such term is defined in the FCPA) or any foreign political party or official thereof or any candidate for foreign political office, in contravention of the
FCPA and the Company and its subsidiary have conducted their businesses in compliance with the FCPA and have instituted and maintain policies and procedures designed to ensure, and which are reasonably expected to continue to ensure, continued
compliance therewith. 
 (b) Neither the Company nor any of its subsidiaries nor, to the knowledge of the Company, any director, officer,
agent, employee, or person acting on behalf of the Company or any subsidiary is currently subject to any U.S. sanctions administered by the Office of Foreign Assets Control of the U.S. Treasury Department (“OFAC”), and the
Company will not directly or indirectly use the proceeds of the sale of the Shares, or lend, contribute or otherwise make available such proceeds to any subsidiary, joint venture partner or other person or entity, towards any sales or operations in
Cuba, Iran, Syria, Sudan, Myanmar or any other country sanctioned by OFAC or for the purpose of financing the activities of any person currently subject to any U.S. sanctions administered by OFAC. 

(c) The operation of each of the Company and its subsidiaries are and have been conducted at all times in compliance with the money laundering
statues of applicable jurisdictions, the rules and regulations thereunder and any related or similar rules, regulations or guidelines, issued, administered or enforced by any applicable governmental agency (collectively, the “Money
Laundering Laws”), and no action suit or proceeding by or before any court of governmental agency, authority or body or any arbitrator involving the Company and/or any subsidiary with respect to the Money Laundering Laws is pending, or
to the Company’s knowledge, threatened. 

  
 -7- 








 2.13 Data Privacy. In connection with its collection, storage, transfer (including,
without limitation, any transfer across national borders) and/or use of any personally identifiable information from any individuals, including, without limitation, any customers, prospective customers, employees and/or other third parties
(collectively “Personal Information”), the Company is and has been in compliance with all applicable laws in all relevant jurisdictions, the Company’s privacy policies and the requirements of any contract or codes of
conduct to which the Company is a party. The Company has commercially reasonable physical, technical, organizational and administrative security measures and policies in place to protect all Personal Information collected by it or on its behalf from
and against unauthorized access, use and/or disclosure. The Company is and has been in compliance in all material respects with all laws relating to data loss, theft and breach of security notification obligations 

2.14 Compliance with Law. The Company has, in all material respects, complied with all laws, regulations and orders applicable
to its present and proposed business and has all material permits and licenses required thereby. There is no term or provision of any mortgage, indenture, contract, agreement or instrument to which the Company is a party or by which it is bound, or,
to the best of the Company’s knowledge, of any provision of any state or federal judgment, decree, order, statute, rule or regulation applicable to or binding upon the Company, which materially adversely affects or, so far as the Company may
now foresee, in the future is reasonably likely to materially adversely affect the Company. To the best of the Company’s knowledge, no employee of the Company is in violation of any term of any contract or covenant (either with the Company or
with another entity) relating to employment, patents, assignment of inventions, proprietary information disclosure, non-competition or non-solicitation. 

2.15 Exemption from Registration, Valid Issuance. Subject to, and in reliance on, the representations, warranties and covenants
made herein by the Investor, the issuance and sale of the Shares in accordance with the terms and on the bases of the representations and warranties set forth in this Agreement, may and shall be properly issued pursuant to Section 4(a)(2) of
the Securities Act, Regulation D promulgated pursuant to the Act (“Regulation D”) and/or any other applicable federal and state securities laws. The sale and issuance of the Shares pursuant to, and the Company’s
performance of its obligations under, this Agreement will not (i) result in the creation or imposition of any liens, charges, claims or other encumbrances upon the Shares or any of the assets of the Company, or (ii) except as set forth in
Section 2.15 of the Schedule of Exceptions, entitle the holders of any outstanding shares of capital stock of the Company to preemptive or other rights to subscribe to or acquire the Shares or other securities of the Company. 

2.16 Taxes. 
 (a)
For purposes of this Agreement: (i) “Tax” or “Taxes” means all taxes, charges, fees, levies or other similar assessments or liabilities, including without limitation income, gross receipts, ad valorem, premium,
value-added, excise, real property, personal property, sales, 

  
 -8- 








 
use, transfer, withholding, employment, unemployment insurance, social security, business license, business organization, environmental, workers compensation, payroll, profits, license, lease,
service, service use, severance, stamp, occupation, windfall profits, customs, duties, franchise and other taxes imposed by the United States of America or any state, local or foreign government, or any other Governmental Entity, and any interest,
fines, penalties, assessments or additions to tax resulting from, attributable to or incurred in connection with any tax or any contest or dispute thereof, and any liability for the payment of the foregoing as a result of being a member of an
affiliated, combined, consolidated or unitary group for any period, as a result of any tax sharing or tax allocation agreement, arrangement or understanding, or as a result of being liable for another person’s taxes as a transferee or
successor, by contractual obligation or otherwise; and (ii) “Tax Returns” means all reports, returns, declarations, statements or other information, including any schedule or attachment thereto, required to be supplied to a
taxing authority in connection with Taxes and any amendment thereof. 
 (b) The amount shown on the Balance Sheet as provision for Taxes is
sufficient in all material respects for the payment of all unpaid Taxes, whether or not disputed, for all periods ending on or before the date thereof. The Company has timely filed or obtained presently effective extensions with respect to all Tax
Returns that are or were required to be filed by it, and such Tax Returns are complete and accurate in all material respects. All Taxes have been timely paid, whether or not shown on such Tax Returns. All Taxes that the Company is or was required by
law to have withheld or collected have been duly withheld or collected and, to the extent required, have been timely paid to the proper Governmental Entity, and the Company has complied with all related recordkeeping requirements. The Tax Returns of
the Company have not been audited by any Governmental Entity, the Company has not agreed to any waivers of statutes of limitations with respect to Taxes, and no controversy with respect to Taxes is pending or, to the best of the Company’s
knowledge, threatened. No claim has ever been made by any Governmental Entity in a jurisdiction where the Company does not file Tax Returns that the Company is or may be subject to taxation by that jurisdiction, and, to the Company’s knowledge,
there is no basis for any such claim to be made. Neither the Company nor any of its stockholders has ever filed an election pursuant to Section 1362 of the Internal Revenue Code of 1986, as amended (the “Code”), that the
Company be taxed as an S corporation. The Company’s net operating losses, as set forth in the Financial Statements, are not subject to any limitations imposed by Section 382 of the Code or comparable provisions of state, local, or foreign
law, and consummation of the transactions contemplated by this Agreement or by any other agreement, understanding or commitment, contingent or otherwise, to which the Company is a party or by which it is otherwise bound will not have the effect of
limiting the Company’s ability to use such net operating losses in full to offset taxable income. The Company does not have any liabilities for Taxes of any other person or entity by contract, as a transferee or successor, under U.S. Treasury
Regulation section 1.1502-6 or analogous state, county, local or foreign provision or otherwise. 
 (c) The Company is not now and has never
been a “United States real property holding corporation” as defined in Section 897(c)(2) of the Code and the Treasury Regulations thereunder. 

  
 -9- 








 2.17 Investment Company. The Company is not an investment company within the
meaning of the Investment Company Act of 1940, as amended. 
 2.18 Shell Company. The Company is not, and has never been, an
issuer identified in Rule 144(i)(1) promulgated under the Securities Act 
 2.19 Brokers. Except as set forth in
Section 2.19 of the Schedule of Exceptions, no brokers, finders or financial advisory fees or commissions will be payable by the Company or any of its subsidiaries in respect of the transactions contemplated by this Agreement. 

2.20 Property and Assets. The Company has good title to, or a valid leasehold interest in, all of its material properties and
assets, including all properties and assets reflected in the Balance Sheet, except those disposed of since the date thereof in the ordinary course of business, and none of such properties or assets is subject to any Security Interest other than
those the material terms of which are described in the Balance Sheet or in the Schedule of Exceptions. 
 2.21 Intellectual
Property. 
 (a) The Schedule of Exceptions includes a complete and accurate list of (i) each patent, patent application,
copyright registration or application therefor, and trademark, service mark and domain name registration or application therefor of the Company and (ii) each Product Candidate (as defined below) owned or in-licensed by the Company. 

(b) To the best of the Company’s Knowledge, the Company is the owner, licensee or has the right to use all Company Intellectual Property
(as defined below) necessary (i) to research, develop, use, manufacture, market and sell the Product Candidates and (ii) to operate the Internal Systems (as defined below). The Company has taken all reasonable measures to protect the
proprietary nature of each item of Company Intellectual Property (as defined below), and to maintain in confidence all trade secrets and confidential information, that it owns or uses. To the best of the Company’s Knowledge, (i) the
patents and patent applications that constitute Company Intellectual Property have been prepared, filed and prosecuted in accordance with all applicable laws and regulations and (ii) any issued patents that constitute Company Intellectual
Property are valid or enforceable. To the best of the Company’s Knowledge, no other person or entity has any rights to any of the Company Intellectual Property owned by the Company (except pursuant to agreements or licenses specified in the
Schedule of Exceptions), and no other person or entity is infringing, violating or misappropriating any of the Company Intellectual Property. To the best of the Company’s Knowledge, there are no pending or threatened legal or governmental
proceedings relating to any Company Intellectual Property, other than ex parte examination proceedings before the US Patent and Trademark Office or ex parte examination proceedings or oppositions before corresponding foreign patent offices. 

(c) To the best of the Company’s Knowledge, as of the date of this Agreement, none of the Product Candidates, or the research,
development, manufacture, marketing, sale, offer to sell, importation, provision or use thereof, infringes or would infringe, or violates or 

  
 -10- 








 
would violate, or constitutes or would constitute a misappropriation of, any Intellectual Property rights of any person or entity. To the best of the Company’s Knowledge, none of the
Internal Systems, or the use thereof, infringes or violates, or constitutes a misappropriation of, any Intellectual Property rights of any person or entity. The Schedule of Exceptions lists any complaint, claim or notice, or written threat thereof,
received by the Company alleging any such infringement, violation or misappropriation; and the Company has provided to the Investor complete and accurate copies of all written documentation in the possession of the Company relating to any such
complaint, claim, notice or threat. The Company has furnished to the Investor complete and accurate copies of all written documentation in the Company’s possession relating to claims or disputes (including without limitation as to validity,
inventorship, ownership or enforceability) known to the Company concerning any Company Intellectual Property. 
 (d) The Schedule of
Exceptions identifies each license or other agreement, including material transfer agreements, pursuant to which the Company has licensed, distributed or otherwise granted any rights to any third party or which the licensor or inventor has granted
any rights with respect to, any Company Intellectual Property. Except as described in the Schedule of Exceptions, the Company has not agreed to indemnify any person or entity against any infringement, violation or misappropriation of any
Intellectual Property rights with respect to any Company Intellectual Property. 
 (e) The Schedule of Exceptions identifies each item of
Company Intellectual Property that is owned by a party other than the Company, and the license or agreement pursuant to which the Company uses it (excluding off-the-shelf software programs licensed by the Company pursuant to “shrink wrap”
or “click through” licenses). 
 (f) All of the copyrightable materials incorporated in, underlying or used with the Company
Intellectual Property have been created by employees of the Company within the scope of their employment by the Company or by independent contractors of the Company who have executed agreements expressly assigning all right, title and interest in
such copyrightable materials to the Company. No portion of such copyrightable materials was jointly developed with any third party. 
 (g)
For purposes of this Agreement (except for the knowledge definition below, which shall be applicable solely to this Section 2.21), the following terms shall have the following meanings: 

(i) “Company Intellectual Property” shall mean the Intellectual Property owned by or licensed to the Company and
incorporated in, underlying or used in connection with the Product Candidates or the Internal Systems, including, without limitation, the patent and trademark rights identified in the Schedule of Exceptions. 

(ii) “Intellectual Property” shall mean all: (A) patents, patent applications, patent disclosures and all
related continuation, continuation-in-part, divisional, reissue, reexamination, utility model, certificate of invention and design patents, patent applications, 

  
 -11- 








 
registrations and applications for registrations; (B) trademarks, service marks, trade dress, Internet domain names, logos, trade names and corporate names and registrations and applications
for registration thereof; (C) copyrights and registrations and applications for registration thereof; (D) computer software, data and documentation; (E) inventions, trade secrets and confidential business information, whether
patentable or nonpatentable and whether or not reduced to practice, know-how, manufacturing and product processes and techniques, formulae, research and development information, copyrightable works, financial, marketing and business data, pricing
and cost information, business and marketing plans and customer and supplier lists and information; (F) other proprietary rights relating to any of the foregoing (including remedies against infringements thereof and rights of protection of
interest therein under the laws of all jurisdictions); and (G) copies and tangible embodiments thereof. 
 (iii) “Internal
Systems” shall mean the internal systems of the Company that are used in its business or operations, including, computer hardware systems, software applications and embedded systems. 

(iv) “Key Employees” shall mean the following officers: Dirk G. Brockstedt, Thomas Dubensky, Jr., Stephen T. Isaacs,
Jennifer Lew and Gregory Schafer. 
 (v) “Knowledge,” including the phrase “to the Company’s
Knowledge,” shall mean the actual knowledge after reasonable investigation of the Key Employees. 
 (vi) “Product
Candidates” shall mean (A) the therapeutic vaccines and other products that the Company (1) currently develops, manufactures, markets, sells or licenses or (2) currently plans to develop, manufacture, market, sell or
license in the future and (B) the services that the Company (1) currently provides or (2) currently plans to provide in the future. 

2.22 Insurance. The Company maintains valid policies of workers’ compensation insurance and of insurance with respect to
its properties and business of the kinds and in the amounts not less than is customarily obtained by corporations of established reputation engaged in the same or similar business and similarly situated, including, without limitation, insurance
against loss, damage, fire, theft, public liability and other risks. 
 2.23 Material Contracts and Obligations. The Schedule
of Exceptions sets forth a list of all material agreements or commitments of any nature (whether written or oral) to which the Company is a party or by which it is bound, including without limitation (a) any agreement which requires future
expenditures by the Company in excess of $500,000 or which might result in payments to the Company in excess of $500,000, (b) any employment agreement, employee benefit, bonus, pension, profit-sharing, stock option, stock purchase or similar
plan or arrangement, (c) any distributor, sales representative or similar agreement, (d) any agreement with any current or former stockholder, officer or director of the Company, or any “affiliate” or “associate” of
such persons (as such terms are defined in the rules and regulations promulgated under the Securities Act), including without limitation any agreement or other arrangement providing for the furnishing of services by, rental of real or personal
property from, or otherwise requiring payments to, any such person or 

  
 -12- 








 
entity, (e) any agreement under which the Company is restricted from carrying on any business anywhere in the world, (f) any agreement relating to indebtedness for borrowed money,
(g) any agreement for the disposition of a material portion of the Company’s assets (other than for the sale of inventory in the ordinary course of business), (h) any agreement for the acquisition of the business or securities or
other ownership interests of another party, (i) any agreement for the license of any patent, copyright, trademark, trade secret or other proprietary right to or from the Company (other than licenses by the Company of “off the shelf”
or other commercially available standard products) or (j) any other agreement that is material to the operations, business or finances of the Company. The Company has furnished to the Investor copies of the foregoing agreements (or an accurate
summary of any oral agreement). All of such agreements and contracts are valid, binding against the Company and in full force and effect. Neither the Company, nor, to the best of the Company’s knowledge, any other party thereto, is in default
of any of its obligations under any of the agreements or contracts listed in the Schedule of Exceptions. 
 2.24 Employees.

 (a) All current and former employees of the Company have executed and delivered Confidential Information and Inventions Assignments and
Non-Solicitation Agreements in the form of Exhibit A and all of such agreements are in full force and effect. All current and former consultants of the Company that have performed development work or provided technical services to the Company
or have otherwise had access to confidential or proprietary information of the Company have executed and delivered non-disclosure and assignment of inventions agreements copies of which have been made available to the Investor, and all of such
agreements are in full force and effect. 
 (b) The Company is not aware that any employee of the Company has plans to terminate his or her
employment relationship with the Company. Except as set forth in Section 2.24(b) of the Schedule of Exceptions, all employees of the Company are engaged by the Company on a full time basis. The Company has complied in all material respects with
all applicable laws relating to wages, hours, equal opportunity, collective bargaining, workers’ compensation insurance and the payment of social security and other Taxes. None of the employees of the Company is represented by any labor union,
and there is no labor strike or other labor trouble pending with respect to the Company (including, without limitation, any organizational drive) or, to the best of the Company’s knowledge, threatened. The Schedule of Exceptions sets forth a
list of all agreements between any officer of the Company and a previous employer of such person that contains non-competition or non-solicitation covenants. The Company has furnished to the Investor copies of such agreements. To the Company’s
knowledge, no employee of the Company is obligated under any contract or subject to any judgment, decree or administrative order that would conflict or interfere with (i) the performance of the employee’s duties as an employee, director or
officer of the Company, or (ii) the Company’s business as conducted or proposed to be conducted. 

  
 -13- 








 (c) The Schedule of Exceptions sets forth (i) the annual salary, (ii) any bonus
arrangements and (iii) rights, options or warrants to subscribe for, purchase or otherwise acquire Common Stock of each of the Key Employees. 

2.25 ERISA. Except as set forth in Section 2.25 of the Schedule of Exceptions, the Company does not have or otherwise
contribute to or participate in any employee benefit plan subject to the Employee Retirement Income Security Act of 1974, as amended, other than a medical benefit plan with respect to which the Company has made all required contributions and has
complied with all applicable laws. 
 2.26 Books and Records. The minute books of the Company contain complete and accurate
records of all meetings and other corporate actions of its stockholders and its Board of Directors and committees thereof. The stock ledger of the Company is complete and accurate and reflects all issuances, transfers, repurchases and cancellations
of shares of capital stock of the Company. 
 2.27 Permits. The Schedule of Exceptions sets forth a list of all material
permits, licenses, registrations, certificates, orders or approvals from any Governmental Entity (“Permits”) issued to or held by the Company. Such listed Permits are the only Permits that are required for the Company to
conduct its business as presently or proposed to be conducted, except for those the absence of which would not have a Company Material Adverse Effect. Each such Permit is in full force and effect and, to the best of the Company’s Knowledge, no
suspension or cancellation of such Permit is threatened and there is no basis for believing that such Permit will not be renewable upon expiration 

2.28 Environmental Matters. 

(a) The Company has complied with all applicable Environmental Laws (as defined below). There is no pending or, to the best of the
Company’s knowledge, threatened civil or criminal litigation, written notice of violation, formal administrative proceeding, or investigation, inquiry or information request by any Governmental Entity, relating to any Environmental Law
involving the Company. For purposes of this Agreement, “Environmental Law” shall mean any federal, state or local law, statute, rule or regulation or the common law relating to the environment or occupational health and
safety, including any statute, regulation, administrative decision or order pertaining to (i) treatment, storage, disposal, generation and transportation of industrial, toxic or hazardous materials or substances or solid or hazardous waste;
(ii) air, water and noise pollution; (iii) groundwater and soil contamination; (iv) the release or threatened release into the environment of industrial, toxic or hazardous materials or substances, or solid or hazardous waste,
including emissions, discharges, injections, spills, escapes or dumping of pollutants, contaminants or chemicals; (v) the protection of wildlife, marine life and wetlands, including all endangered and threatened species; (vi) storage
tanks, vessels, containers, abandoned or discarded barrels and other closed receptacles; (vii) health and safety of employees and other persons; and (viii) manufacturing, processing, using, distributing, treating, storing, disposing,
transporting or handling of materials 

  
 -14- 








 
regulated under any law as pollutants, contaminants, toxic or hazardous materials or substances or oil or petroleum products or solid or hazardous waste. As used above, the terms
“release” and “environment” shall have the meaning set forth in the federal Comprehensive Environmental Response, Compensation and Liability Act of 1980, as amended (“CERCLA”), provided that
the term “release” shall not include the definitional exclusions of CERCLA and the term “environment” shall not include the United States jurisdictional limitations of CERCLA and shall include the
indoor environment. 
 (b) The Company has no liabilities or obligations arising from the release of any Materials of Environmental Concern
(as defined below) into the environment. For purposes of this Agreement, “Materials of Environmental Concern” shall mean any chemicals, pollutants or contaminants, hazardous substances (as such term is defined under CERCLA),
solid wastes and hazardous wastes (as such terms are defined under the Resource Conservation and Recovery Act), toxic materials, oil or petroleum and petroleum products or any other material subject to regulation under any Environmental Law. 

(c) The Company is not a party to or bound by any court order, administrative order, consent order or other agreement between the Company and
any Governmental Entity entered into in connection with any legal obligation or liability arising under any Environmental Law. 
 (d) The
Company is not aware of any material environmental liability of any solid or hazardous waste transporter or treatment, storage or disposal facility that has been used by the Company. 

(e) Set forth in the Schedule of Exceptions is a list of all documents (whether in hard copy or electronic form) that contain any
environmental reports, investigations and audits relating to premises currently or previously owned or operated by the Company (whether conducted by or on behalf of the Company or a third party, and whether done at the initiative of the Company or
directed by a Governmental Entity or other third party) which the Company has possession of or access to. A complete and accurate copy of each such document has been provided to the Investor. 

2.29 Disclosure. Neither this Agreement nor any Exhibit hereto, nor any report, certificate or instrument furnished by
the Company to any of the Investor or its counsel in connection with the transactions contemplated by this Agreement, when read together, contains or will contain any untrue statement of a material fact or omits or will omit to state a material fact
necessary in order to make the statements contained herein or therein, in light of the circumstances under which they were made, not misleading. 

2.30 Bad Actors Matters. Neither the Company nor, to the Company’s knowledge, any of its officers, directors or other
affiliates covered under Rule 506(d)(1) promulgated under the Securities Act (excluding for such purposes the Investor) meet any of the disqualifying criteria described in Rule 506(d)(1)(i) through (viii) promulgated under the Securities Act.


  
 -15- 








 SECTION 3 

Representations and Warranties of the Investor 

The Investor hereby represents and warrants the following as of the date hereof and as of the Closing Date: 

3.1 Experience. The Investor has carefully reviewed the representations concerning the Company contained in this Agreement and
has sufficient knowledge and experience in finance and business that it is capable of evaluating the risks and merits of its investment in the Company and the Investor is able financially to bear the risks thereof. 

3.2 Investment. The Investor is acquiring the Shares for investment for the Investor’s own account and not with the view
to, or for resale in connection with, any distribution thereof. The Investor understands that the Shares are being issued in a transaction that has not been and will not be registered under the Securities Act by reason of a specific exemption from
the registration provisions of the Securities Act which depends upon, among other things, the bona fide nature of the investment intent as expressed herein. The Investor further represents that it does not have any contract, undertaking, agreement
or arrangement with any person to sell, transfer or grant participation to any third person with respect to any of the Shares. 
 3.3
Rule 144. The Investor acknowledges that the Shares must be held indefinitely unless subsequently registered under the Securities Act or an exemption from such registration is available. The Investor is aware of the provisions of Rule
144 promulgated under the Securities Act which permit limited resale of shares purchased in a private placement subject to the satisfaction of certain conditions. In connection therewith, the Investor acknowledges that the Company will make a
notation on its stock books regarding the restrictions on transfers set forth in this Section 3 and will transfer the Shares on the books of the Company only to the extent not inconsistent therewith. 

3.4 Access to Information. The Investor has received and reviewed information about the Company and has had an opportunity to
discuss the Company’s business, management and financial affairs with its management and to review the Company’s facilities. The Investor has had a full opportunity to ask questions of and receive answers from the Company, or any person or
persons acting on behalf of the Company, concerning the terms and conditions of an investment in the Shares. In connection with the purchase of the Shares hereunder, the Investor is not relying upon, and has not relied upon, any statement,
representation or warranty made by any person, except for the statements, representations and warranties contained in this Agreement. 
 3.5
Authorization. The Investor has full power and authority to enter into and to perform this Agreement in accordance with its terms. The Investor represents that it has not been organized, reorganized or recapitalized specifically for
the purpose of investing in the Company. 

  
 -16- 








 
This Agreement has been duly executed and delivered by the Investor and constitutes a valid and binding obligation of the Investor enforceable against the Investor in accordance with their
respective terms. 
 3.6 Investor Status. The Investor acknowledges that it is either (i) an institutional
“accredited investor” as defined in Rule 501(a) of Regulation D of the Securities Act (an “Institutional Accredited Investor”) or (ii) a “qualified institutional buyer” as defined in Rule 144A of the
Securities Act, as indicated on Schedule A hereto, and the Investor shall submit to the Company such further assurances of such status as may be reasonably requested by the Company. 

3.7 No Inducement. The Investor was not induced to participate in the offer and sale of the Shares by the filing of any
registration statement in connection with any public offering of the Company’s securities, and the Investor’s decision to purchase the Shares hereunder was not influenced by the information contained in any such registration statement.

 SECTION 4 

Conditions to Investor’s Obligations at Closing 

The obligations of the Investor under this Agreement are subject to the fulfillment on or before the Closing of each of the following
conditions, any of which may be waived in writing by the Investor (except to the extent not permitted by law): 
 4.1 No Injunction,
etc. No preliminary or permanent injunction or other binding order, decree or ruling issued by a court or governmental agency shall be in effect which shall have the effect of preventing the consummation of the transactions contemplated by
this Agreement. No action or claim shall be pending before any court or quasi-judicial or administrative agency of any federal, state, local or foreign jurisdiction or before any arbitrator wherein an unfavorable injunction, judgment, order, decree,
ruling or charge would be reasonably likely to (i) prevent consummation of any of the transactions contemplated by this Agreement, (ii) cause any of the transactions contemplated by this Agreement to be rescinded following consummation or
(iii) have the effect of making illegal the purchase of, or payment for, any of the Shares by the Investor. 
 4.2
Representations and Warranties. The representations and warranties of the Company contained in Section 2 shall have been true and correct in all material respects (except for such representations and warranties that are qualified
by materiality, which shall be true and correct in all respects, and for the representations and warranties contained in Section 2.6, which shall be true and correct in all respects other than de minimis exceptions) on and as of the
Closing Date, with the same effect as though such representations and warranties had been made on and as of such date, except to the extent expressly made as of a specified date, which shall be true and correct as of such date. 

  
 -17- 








 4.3 Performance. The Company shall have performed and complied with all covenants,
agreements, obligations and conditions contained in this Agreement that are required to be performed or complied with by it on or before the Closing Date. 

4.4 Compliance Certificate. A duly authorized officer of the Company shall deliver to the Investor at the Closing a certificate
stating that the conditions specified in Sections 4.2 and 4.3 have been fulfilled and certifying and attaching the Company’s Certificate of Incorporation, Bylaws and authorizing Board of Directors resolutions with respect to this Agreement and
the transactions contemplated hereby, and shall further certify that under the Restated Certificate 4,722,058 shares have been designated as Series E Preferred, 2,361,029 of which are issued or outstanding. 

4.5 Securities Laws. The offer and sale of the Shares to the Investor pursuant to this Agreement shall be exempt from the
registration requirements of the Securities Act and the registration and/or qualification requirements of all applicable state securities laws. 

4.6 Authorizations. All authorizations, approvals or permits, if any, of any governmental authority or regulatory body that are
required in connection with the lawful issuance and sale of the Shares pursuant to this Agreement shall have been duly obtained and shall be effective on and as of the Closing. 

4.7 Legal Opinion. The Investor shall have received a legal opinion from Cooley LLP substantially in form and substance
reasonably acceptable to the Investor. 
 4.8 Effective Date. The Effective Date (as such term is described in the that
certain Collaboration and License Agreement (the “Collaboration Agreement”), entered into as of March 12, 2015, between the Company and Novartis Pharmaceuticals Corporation) shall have occurred. 

4.9 Closing of First Tranche Purchase Agreement. The closing of the transactions contemplated by the First Tranche Purchase
Agreement shall have occurred. 
 SECTION 5 

Conditions to the Company’s Obligations at Closing 

The obligations of the Company to the Investor under this Agreement are subject to the fulfillment on or before the Closing of each of the
following conditions by the Investor: 
 5.1 Representations and Warranties. The representations and warranties of the
Investor contained in Section 3 shall be true and correct in all material respects (except for such representations and warranties that are qualified by materiality which shall be true and correct in all respects) on and as of the Closing with
the same effect as though such representations and warranties had been made on and as of the Closing. 

  
 -18- 








 5.2 Securities Law Compliance. The offer and sale of the Shares to the Investor
pursuant to this Agreement shall be exempt from the registration requirements of the Securities Act and the registration and/or qualification requirements of all applicable state securities laws. 

5.3 Authorization. All authorizations, approvals or permits, if any, of any governmental authority or regulatory body
that are required in connection with the lawful issuance and sale of the Shares pursuant to this Agreement shall have been duly obtained and shall be effective on and as of the Closing. 

SECTION 6 
 Investor
Covenants 
 6.1 Trading Restrictions. 

(a) Definitions. 
 (i)
“Affiliate” shall have the meaning set forth in Rule 12b-2 of the regulations promulgated under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). 

(ii) “Restriction Period” shall mean the period commencing on the Closing Date and continuing until the earlier of
(A) the two year anniversary of the Closing Date and (B) the date upon which the Collaboration Agreement expires or is terminated in accordance with its terms. 

(iii) “Standstill Period” shall mean the period commencing on the Effective Date and continuing until the earlier of
(i) the two year anniversary thereof and (ii) the date upon which the Collaboration Agreement expires or is terminated in accordance with its terms. 

(iv) “Significant Event” shall mean any of the following not involving a violation of this Section 6: (A) the
public announcement of a proposal or intention to acquire, or the acquisition, by any person or 13D Group of beneficial ownership of Voting Securities representing 15% or more of the then outstanding Voting Securities, or all or substantially all of
the assets of the Company; (B) the public announcement of a proposal or intention to commence, or the commencement, by any person or 13D Group of a tender or exchange offer to acquire Voting Securities which, if successful, would result in such
person or 13D Group owning, when combined with any other Voting Securities owned by such person or 13D Group, 15% or more of the then outstanding Voting Securities; (C) the entry into by the Company, or the public announcement by the Company of
an intention or determination to enter into or commence or continue any discussions relating to, any merger, sale or other business combination transaction, or an agreement therefor, pursuant to which the outstanding shares of capital stock of the
Company would be converted into cash, other consideration or securities of another person or 13D Group or 50% or more of the then 

  
 -19- 








 
outstanding shares of capital stock of the Company would be owned by persons other than the then current holders of shares of capital stock of the Company, or which would result in all or a
substantial portion of the Company’s assets being sold to any person or 13D Group, or (D) entering into an agreement or commencing a proxy solicitation in which a person or 13D Group would, if successful, elect, or acquire the ability to
elect, a majority of the Board of Directors of the Company. 
 (v) “Voting Securities” shall mean at any time shares of
any class of capital stock of the Company which are then entitled to vote generally in the election of directors. 
 (vi) “13D
Group” shall mean, with respect to the Voting Securities of the Company, any group of persons formed for the purpose of acquiring, holding, voting or disposing of such Voting Securities which would be required under Section 13(d) of
the Exchange Act and the rules and regulations thereunder to file a statement on Schedule 13D with the Commission as a “person” within the meaning of Section 13(d)(3) of the Exchange Act if such group beneficially owned Voting
Securities representing more than 5% of the total combined voting power of all such Voting Securities then outstanding. 
 (b)
Restriction Period No Sell. The Investor agrees that during the Restriction Period, neither the Investor nor any of its Affiliates shall offer, sell, contract to sell, pledge, grant any option to purchase, make any short sale or otherwise
dispose of in any manner, either directly or indirectly (“Sale” or “Sell”), any Shares or any securities of the Company issued as a dividend or distribution on, or involving a recapitalization or
reorganization with respect to, any of the Shares (“Covenant Shares”), other than transfers of securities between and among the Investor and any one or more of its Affiliates. The Company shall use commercially reasonable
efforts to permit the Shares to be eligible for clearance and settlement through the facilities of The Depository Trust Company immediately following the termination of the Restriction Period. 

(c) Post-Restriction Period Selling Restrictions. During the two years following the expiration of the Restriction Period: 

(i) Neither the Investor nor its Affiliates shall Sell a number of Covenant Shares in any three-month period that collectively exceeds 25% of
the aggregate Covenant Shares held by the Investor and its Affiliates as of the end of the Restriction Period; and 
 (ii) For any proposed
Sale of 100,000 or more shares of Common Stock of the Company by the Investor or any of its Affiliates in any single transaction or series of related transactions (“Proposed Sale Shares”), the Investor shall give the Company
at least 10 days prior written notice of such sale. If the Investor provides a notice as provided in the preceding sentence, during such 10-day period, the Company may seek to find a buyer for the Proposed Sale Shares. The limitations and
obligations set forth in this Section 6.1(c) shall not apply to any Sale of Covenant Shares taking place between the Investor (and/or any of its Affiliates) and a single buyer; provided that the Investor shall give the Company at least 30 days prior
written notice of such Sale. 

  
 -20- 








 
This Section 6.1(c) shall terminate one year after the expiration or termination of the Collaboration Agreement in accordance with its terms, if such termination occurs prior to the one year
anniversary of the expiration of the Restriction Period. 
 (d) Standstill. The Investor agrees that during the Standstill Period,
neither the Investor nor any of its Affiliates shall: 
 (i) make any statement or proposal to the board of directors of any of the
Company, any of the Company’s representatives or any of the Company’s stockholders regarding, or make any public announcement, proposal or offer (including any “solicitation” of “proxies” as such terms are defined or
used in Regulation 14A of the Exchange Act) with respect to, or otherwise solicit, seek or offer to effect (including, for the avoidance of doubt, indirectly by means of communication with the press or media) (i) any business combination,
merger, tender offer, exchange offer or similar transaction involving the Company or any of its subsidiaries, (ii) any restructuring, recapitalization, liquidation or similar transaction involving the Company or any of its subsidiaries,
(iii) any acquisition of any of the Company’s loans, debt securities, equity securities or all or substantially all of the Company’s assets, or rights or options to acquire interests in any of the foregoing, (iv) any proposal to
seek representation on the board of directors of the Company or otherwise seek to control or influence the management, board of directors or policies of any of the Company or (v) any request or proposal to waive, terminate or amend the
provisions of this Section 6.1(d) or (vi) any proposal, arrangement or other statement that is inconsistent with the terms of this Section 6.1(d); 

(ii) instigate, encourage or assist any third party (including forming a “group,” as defined in the Exchange Act, with any such
third party) to do, or enter into any discussions or agreements with any third party with respect to, any of the actions set forth in clause (i) above; 

(iii) take any action which would reasonably be expected to require the Company or any of its affiliates to make a public announcement
regarding any of the actions set forth in clause (i) above; or 
 (iv) acquire (or propose or agree to acquire), of record or
beneficially, by purchase or otherwise, any loans, equity securities or all or substantially all of the assets of the Company or any of its subsidiaries, or rights or options to acquire interests in any of the foregoing. 

Notwithstanding the foregoing, this Section 6.1(d) shall not prohibit the Investor and any of its Affiliates from privately discussing
any potential transaction with the Company, or from acquiring and beneficially owning up to ten percent (10%) of the Company’s outstanding equity securities (and the Investor and its Affiliates may own an amount in excess of such
percentage solely to the extent exclusively resulting from actions taken or permitted by the Company following the acquisition by the Investor and/or its Affiliates of the Company’s equity securities, including as a result of a repurchase by
the Company of equity securities, any stock split, stock dividend or a recapitalization of the Company). 

  
 -21- 








 (e) Occurrence of Significant Event. The restrictions contained in Sections 6.1(b), 6.1(c)
and 6.1(d) shall be suspended and shall not apply to or otherwise restrict the Investor’s actions in respect of the Company’s securities for so long as a Significant Event has occurred and is continuing. 

6.2 Invalid Transfers. Any sale, assignment or other transfer of Covenant Shares by the Investor or any of its Affiliates, as
applicable, contrary to the provisions of this Section 6 shall be null and void, and the transferee shall not be recognized by the Company as the holder or owner of the Covenant Shares sold, assigned, or transferred for any purpose (including,
without limitation, voting or dividend rights), unless and until the Investor or such Affiliate, as applicable, has satisfied the requirements of this Section 6 with respect to such sale. The Company, or, at the instruction of the Company, the
transfer agent of the Company, may place a legend on any certificate representing Covenant Shares stating that such shares are subject to the restrictions contained in this Agreement. Upon expiration of the Restriction Period, the Company agrees to
facilitate the timely preparation and delivery (but in no event longer than three (3) business days) of certificates representing the Covenant Shares to be sold by the Investor or any Affiliate free of any restrictive legends and in such
denominations and registered in such names as the Investor or such Affiliate may request in connection with such sale. 
 6.3
Performance by Affiliates. The Investor shall remain responsible for and guarantee its Affiliates’ performance in connection with this Agreement, and shall cause each such Affiliate to comply fully with the provisions of
this Agreement in connection with such performance. The Investor hereby expressly waives any requirement that the Company exhaust any right, power or remedy, or proceed directly against such an Affiliate, for any obligation or performance hereunder,
prior to proceeding directly, against the Investor. 
 6.4 Voting Agreement. The Investor agrees to be bound by and comply
with the terms of that certain Amended and Restated Voting Agreement, dated as of December 19, 2014, among the Company, the Purchasers listed on Exhibit A thereto and the Key Holders listed on Exhibit B thereto (the “Voting
Agreement”) as a “Purchaser,” and the Shares shall be deemed “Shares” under the Voting Agreement, the terms of which are incorporated herein mutatis mutandis. 

SECTION 7 
 Registration
Rights 
 7.1 Rule 144 Reporting. With a view to making available to the Investor the benefits of certain rules and
regulations of the Commission which may permit the sale of the Shares to the public without registration, the Company agrees to use commercially reasonable efforts to: 

(a) Make and keep public information available, as those terms are understood and defined in Rule 144 promulgated under the Securities Act;


  
 -22- 








 (b) File with the Commission in a timely manner all reports and other documents required of the
Company under the Exchange Act; and 
 (c) Furnish the Investor forthwith upon request (i) a written statement by the Company as to its
compliance with the public information requirements of said Rule 144, (ii) a copy of the most recent annual or quarterly report of the Company, and (iii) such other reports and documents as may be reasonably requested in availing the
Investor of any rule or regulation of the Commission permitting the sale of any such securities without registration. 
 7.2
Registration. 
 (a) If, at the end of the Restriction Period, the Shares cannot be sold without restriction pursuant to Rule
144 promulgated under the Securities Act, then upon Investor’s written request, received by the Company on or before the 30th day after the end of the Restriction Period, the Company will use commercially reasonable efforts to register the
Shares for resale under the Securities Act on a Registration Statement on Form S-3 (the “Registration Statement”), filed within 90 days of such written request, and will use commercially reasonable efforts to have such
Registration Statement promptly declared effective by the Commission. 
 (b) The Company will use commercially reasonable efforts to keep
the Registration Statement continuously effective under the Securities Act until the earlier of (i) the date all of the Shares covered by such Registration Statement have been sold or can be sold publicly without restriction or limitation under
Rule 144 or (ii) the date that is two years following the Closing Date. 
 (c) The Investor shall furnish to the Company such
information regarding the Investor, and the distribution proposed by the Investor, as the Company may reasonably request in writing and as shall be required in connection with the Registration Statement. 

(d) The Company shall pay all fees and expenses incident to the performance of or compliance with this Section 7.2 by the Company. 

7.3 Restrictive Legend. 

(a) The certificates representing the Shares, when issued, will bear a restrictive legend in substantially the following form: 

“THE SECURITIES EVIDENCED OR CONSTITUTED HEREBY HAVE BEEN ISSUED WITHOUT REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE
“ACT”) AND MAY NOT BE SOLD, OFFERED FOR SALE, TRANSFERRED, PLEDGED OR HYPOTHECATED WITHOUT REGISTRATION UNDER THE ACT UNLESS EITHER (i) THE COMPANY HAS RECEIVED AN OPINION OF COUNSEL, IN FORM AND SUBSTANCE REASONABLY SATISFACTORY TO
THE COMPANY, TO THE EFFECT THAT REGISTRATION IS NOT REQUIRED IN CONNECTION WITH SUCH DISPOSITION OR (ii) THE SALE OF SUCH SECURITIES IS MADE PURSUANT TO RULE 144 PROMULGATED UNDER THE ACT.” 

  
 -23- 








 (b) The certificates representing the Shares, when issued, shall not bear the restrictive legend
set forth in Section 7.3(a): (i) following a sale of such Shares pursuant to a registration statement covering the resale of such Shares, while such registration statement is effective under the Securities Act, (ii) following any sale
of such Shares pursuant to Rule 144 promulgated under the Securities Act (“Rule 144”), (iii) if such Shares are eligible for sale under Rule 144, without the requirement for the Company to be in compliance with the
current public information required under Rule 144 as to such Shares and without volume or manner-of-sale restrictions or (iv) if such legend is not required under applicable requirements of the Securities Act (including judicial
interpretations and pronouncements issued by the staff of the Securities and Exchange Commission). The Company agrees that at such time as the restrictive legend set forth in Section 7.3(a) is no longer required under this section, the Company
will (x) no later than five (5) business days following the delivery by the Investor to the Company or the Company’s transfer agent of a certificate representing Shares issued with such restrictive legend, deliver or cause to be
delivered to the Investor a certificate representing such Shares that is free from such restrictive legend, and (y), in the event that such shares are uncertificated, no later than five (5) business days following the delivery of a written
request by the Investor to the Company to remove such restrictive legend, remove, or cause to be removed, any such restrictive legend in the Company’s stock records. The Company may not make any notation on its records or give instructions to
the Company’s transfer agent that enlarge the restrictions on transfer set forth in Sections 6.2, 7.3(a) and 7.4. 
 7.4
“Lock-Up” Agreement; Confidentiality of Notices. The Investor agrees, if requested by the Company and the managing underwriter of an underwritten initial public offering of the Company’s Common Stock (an
“IPO”) (but not for any subsequent offerings) (i) not to (a) offer, pledge, announce the intention to sell, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell,
grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any Shares or other securities of the Company (excluding securities acquired in the public market after the IPO) or (b) enter into any
swap or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of any Shares or other securities of the Company (excluding securities acquired in the public market after the IPO), whether any transaction
described in clause (a) or (b) is to be settled by delivery of securities, in cash or otherwise, during the period beginning on the date of the filing of such registration statement with the Securities and Exchange Commission and ending on
the date specified by the Company and the managing underwriter (such period not to exceed 180 days in the case of an IPO or such other period not to exceed 18 days after the expiration of the 180-day period, as may be requested by the Company or an
underwriter to accommodate regulatory restrictions on (1) the publication or other distribution of research reports, and (2) analyst recommendations and opinions, including, but not limited to, the restrictions contained in FINRA Rule
2711(f)(4) or NYSE Rule 472(f)(4), or any successor provisions or amendments thereto), and (ii) to execute any agreement reflecting clause (i) above as may be requested by the Company or the managing underwriters at the time of such
offering. 

  
 -24- 








 The Company may impose stop-transfer instructions with respect to the Registrable Shares or other
securities subject to the foregoing restriction until the end of such “lock-up” period. 
 As a condition to the obligation of the
Investor under this Section 7.4, any “lock-up” obligation of the Investor under this Section 7.4, and any agreement entered into by the Investor as a result of its obligations under this Section 7.4, shall allow for periodic
early releases of portions of the securities subject to such “lock-up” obligations, which may be conditioned upon the trading price of the Company’s Common Stock. 

If the Investor receives any written notice from the Company regarding the Company’s plans to file a Registration Statement, the Investor
shall treat such notice confidentially and shall not disclose such information to any person other than as necessary to exercise its rights under this Agreement. 

SECTION 8 

Indemnification 
 Each
party (an “Indemnifying Party”) hereby indemnifies and holds harmless the other party, such other party’s respective officers, directors, employees, consultants, representatives and advisers, and any and all Affiliates
(as defined in Section 6.1(a)) of the foregoing (each of the foregoing, an “Indemnified Party”) from and against all losses, liabilities, costs, damages and expense (including reasonable legal fees and expenses)
(collectively, “Losses”) suffered or incurred by any such Indemnified Party to the extent arising from, connected with or related to (i) breach of any representation or warranty of such Indemnifying Party in this
Agreement; and (ii) breach of any covenant or undertaking of any Indemnifying Party in this Agreement. If an event or omission (including, without limitation, any claim asserted or action or proceeding commenced by a third party) occurs which
an Indemnified Party asserts to be an indemnifiable event pursuant to this Section 8, the Indemnified Party will provide written notice to the Indemnifying Party, setting forth the nature of the claim and the basis for indemnification under
this Agreement. The Indemnified Party will give such written notice to the Indemnifying Party immediately after it becomes aware of the existence of any such event or occurrence. Such notice will be a condition precedent to any obligation of the
Indemnifying Party to act under this Agreement but will not relieve it of its obligations under the indemnity except to the extent that the failure to provide prompt notice as provided in this Agreement prejudices the Indemnifying Party with respect
to the transactions contemplated by this Agreement and to the defense of the liability. In case any such action is brought by a third party against any Indemnified Party and it notifies the Indemnifying Party of the commencement thereof, the
Indemnifying Party will be entitled to participate therein and, to the extent that it wishes, to assume the defense and settlement thereof with counsel reasonably selected by it and, after notice from the Indemnifying Party to the Indemnified Party
of such election so to assume the defense and settlement thereof, the Indemnifying Party will not be liable to the Indemnified Party for any legal expenses of other counsel or any other expenses subsequently incurred by such Indemnified Party in
connection with the defense thereof, provided, however, that 

  
 -25- 








 
an Indemnified Party shall have the right to employ separate counsel at the expense of the Indemnifying Party if (i) the employment thereof has been specifically authorized in writing by the
Indemnifying Party; or (ii) representation of both parties by the same counsel would be inappropriate due to actual or potential conflicts of interests between such parties (which such judgment shall be made in good faith after consultation
with counsel). The Indemnified Party agrees to cooperate fully with (and to provide all relevant documents and records and make all relevant personnel available to) the Indemnifying Party and its counsel, as reasonably requested, in the defense of
any such asserted claim at no additional cost to the Indemnifying Party. No Indemnifying Party will consent to the entry of any judgment or enter into any settlement with respect to any such asserted claim without the prior written consent of the
Indemnified Party, not to be unreasonably withheld or delayed, (a) if such judgment or settlement does not include as an unconditional term thereof the giving by each claimant or plaintiff to each Indemnified Party of a release from all
liability in respect to such claim or (b) if, as a result of such consent or settlement, injunctive or other equitable relief would be imposed against the Indemnified Party or such judgment or settlement could materially and adversely affect
the business, operations or assets of the Indemnified Party. No Indemnified Party will consent to the entry of any judgment or enter into any settlement with respect to any such asserted claim without the prior written consent of the Indemnifying
Party, not to be unreasonably withheld or delayed. If an Indemnifying Party makes a payment with respect to any claim under the representations or warranties set forth herein and the Indemnified Party subsequently receives from a third party or
under the terms of any insurance policy a sum in respect of the same claim, the receiving party will repay to the other party such amount that is equal to the sum subsequently received. 

SECTION 9 

Miscellaneous 
 9.1
Information and Other Rights. 
 (a) For so long as the Investor continues to hold at least 2,250,000 shares of Series E
Preferred and/or Common Stock, and until the earlier of the closing of a Company Sale or a Qualified IPO (each as defined in the Amended and Restated Investor Rights Agreement, dated as of December 19, 2014, among the Company and the
individuals and entities listed on Exhibit A thereto (the “Investor Rights Agreement”), the Company shall provide the Investor with the information set forth in Sections 4.4(a)(i), (ii) and (iv) of the Investor
Rights Agreement, the terms of which are incorporated herein mutatis mutandis. 
 (b) For so long as the Investor continues to hold
any shares of Series E Preferred, and until the earlier of the closing of a Company Sale or a Qualified IPO, the Company hereby makes the covenants and agreements set forth in Section 4.2 of the Investor Rights Agreement, the terms of which are
incorporated herein mutatis mutandis. 

  
 -26- 








 (c) For so long as the Investor continues to hold any shares of Series E Preferred or Common
Stock issuable upon the conversion thereof, and until the earlier of the closing of a Company Sale or a Qualified IPO, the Company hereby makes the covenants and agreements set forth in Sections 4.5, 4.6, 4.7, 4.9, 4.10 and 4.11 of the Investor
Rights Agreement, the terms of which are incorporated herein mutatis mutandis. 
 9.2 Governing Law. This Agreement
shall be governed in all respects by the laws of the State of Delaware (without reference to the conflicts of law provisions thereof). 

9.3 Survival. The representations, warranties, covenants and agreements made herein shall survive any investigation made by the
Investor and the Closing. 
 9.4 Successors, Assigns. Except as otherwise provided herein, the provisions hereof shall inure
to the benefit of, and be binding upon, the successors, assigns, heirs, executors and administrators of the parties hereto. This Agreement may not be assigned by either party without the prior written consent of the other; except that either party
may assign this Agreement to an Affiliate (as defined in Section 6.1(a)) of such party or to any third party that acquires all or substantially all of such party’s business, whether by merger, sale of assets or otherwise. 

9.5 Notices. All notices and other communications required or permitted hereunder shall be in writing and shall be sent by
facsimile (receipt confirmed) or mailed by registered or certified mail, postage prepaid, return receipt requested, or otherwise delivered by hand or by messenger, addressed 

if to the Investor, at the following address: 

Novartis Institutes for BioMedical Research, Inc. 

250 Massachusetts Avenue 

Cambridge, MA 02139 
 Attention:
General Counsel 
 Facsimile: (617) 871-5786 

with a copy (which shall not constitute notice) to: 

Kaye Scholer LLP 
 250 West 55th Street 
 New York, New York 10019-9710 

Attention: Thomas Yadlon 

Facsimile: (212) 836-6567 

if to the Company, at the following address: 

Aduro Biotech, Inc. 
 626 Bancroft
Way #3C 

  
 -27- 








 Berkeley, CA 94710 

Attention: President 
 Facsimile:
(510) 848-5614 
 with a copy (which shall not constitute notice) to: 

Cooley LLP 
 3175 Hanover Street

 Palo Alto, California 94304 

Attention: Michael Tenta 

Facsimile: (650) 849-7400 
 or at such other
address as one party shall have furnished to the other party in writing. If notice is provided by facsimile, it shall be deemed to be given one (1) business day after transmission (with receipt of appropriate confirmation). If notice is
provided by U.S. mail, notice shall be deemed to be given four (4) days after proper deposit in a U.S. mailbox, postage prepaid, and properly addressed. If notice is provided by a messenger service that guarantees “next business day”
delivery, it shall be deemed effective one (1) business day after deposit with such messenger service. 
 9.6 Expenses.
Each of the Company and the Investor shall bear its own expenses and legal fees incurred on its behalf with respect to this Agreement and the transactions contemplated hereby. 

9.7 Confidentiality. 

(a) Subject to the other provisions of this Section 9.7, the existence of this Agreement and the terms and conditions of this Agreement
(collectively, the “Confidential Information”) will be maintained in confidence and otherwise safeguarded by the parties to this Agreement. Subject to the other provisions of this Section 9.7, each party shall hold as
confidential such Confidential Information in the same manner and with the same protection as such party maintains its own confidential information. Subject to the other provisions of this Section 9.7, a party may only disclose Confidential
Information to its employees, representatives, agents, sublicensees, subcontractors, consultants and advisers and its affiliates to the extent reasonably necessary for the purposes of, and for those matters undertaken pursuant to, this Agreement;
provided that such persons are bound to maintain the confidentiality of the Confidential Information in a manner consistent with the confidentiality provisions of this Agreement. 

(b) The obligations under this Section 9.7 shall not apply to any information to the extent the disclosing party can demonstrate by
competent evidence that such information is (at the time of disclosure) or becomes (after the time of disclosure) known to the public or part of the public domain through no breach of this Agreement by such party or its affiliates. 

(c) In addition to disclosures allowed under Section 9.7(b), each party may disclose Confidential Information solely to the extent such
disclosure is necessary in the following 

  
 -28- 








 
instances: (i) complying with applicable law, court orders or governmental regulations, including rules of self-regulatory organizations and Securities and Exchange Commission filing and
disclosure requirements or (ii) to potential or actual investors or acquirers as may be necessary in connection with their evaluation of a potential or actual investment or acquisition; provided that such persons shall be subject to obligations
of confidentiality and non-use at least as protective as those set forth in this Section 9.7. 
 (d) In the event a party is required
to disclose Confidential Information by law, applicable court order or governmental regulation or in connection with bona fide legal process, such disclosure shall not be a breach of this Agreement; provided that such party (i) informs the
other party as soon as reasonably practicable of the required disclosure; (ii) limits the disclosure to that which is legally required to be disclosed; and (iii) at the other party’s request and expense, assists in an attempt to
object to or limit the required disclosure. 
 (e) Either party may disclose the existence and terms of this Agreement in confidence to its
attorneys and advisors, and to potential acquirers (and their respective professional attorneys and advisors), in connection with a potential merger, acquisition or reorganization and to existing and potential investors or lenders of such party, as
part of their due diligence investigations, or to existing and potential licensees or sublicensees or to permitted assignees, in each case under an agreement to keep the terms of confidentiality and non-use substantially no less rigorous than the
terms contained in this Agreement and to use such information solely for the purpose permitted pursuant to this Section 9.7(e). 
 9.8
Finder’s Fees. Each of the Company and the Investor shall indemnify and hold the other harmless from any liability for any commission or compensation in the nature of a finder’s fee, placement fee or underwriter’s
discount (including the costs, expenses and legal fees of defending against such liability) for which the Company or the Investor, or any of its respective partners, employees, or representatives, as the case may be, is responsible. 

9.9 Counterparts. This Agreement may be executed in counterparts, each of which shall be enforceable against the party actually
executing the counterpart, and all of which together shall constitute one instrument. 
 9.10 Severability. In the event that
any provision of this Agreement becomes or is declared by a court of competent jurisdiction to be illegal, unenforceable or void, this Agreement shall continue in full force and effect without said provision; provided that no such severability shall
be effective if it materially changes the economic benefit of this Agreement to any party. 
 9.11 Entire Agreement. This
Agreement, including the exhibits and schedule attached hereto, constitute the full and entire understanding and agreement among the parties with regard to the subjects hereof and thereof. No party shall be liable or bound to any other party in any
manner with regard to the subjects hereof or thereof by any warranties, representations or covenants except as specifically set forth herein or therein. 

  
 -29- 








 9.12 Waiver. The failure of either party to assert a right hereunder or to insist
upon compliance with any term or condition of this Agreement shall not constitute a waiver of that right or excuse a similar subsequent failure to perform any such term or condition by the other party. None of the terms, covenants and conditions of
this Agreement can be waived except by the written consent of the party waiving compliance. 
 9.13 Termination. This
Agreement shall terminate automatically if the Collaboration Agreement is terminated pursuant to its terms prior to the consummation of the Closing. 

[This space left intentionally blank. Signature page follows.] 

  
 -30-